WO1998018465A1 - Use of antagonists of substance p for treating tardive diskinesia - Google Patents

Use of antagonists of substance p for treating tardive diskinesia Download PDF

Info

Publication number
WO1998018465A1
WO1998018465A1 PCT/FR1997/001914 FR9701914W WO9818465A1 WO 1998018465 A1 WO1998018465 A1 WO 1998018465A1 FR 9701914 W FR9701914 W FR 9701914W WO 9818465 A1 WO9818465 A1 WO 9818465A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
optionally substituted
class
substituted
Prior art date
Application number
PCT/FR1997/001914
Other languages
French (fr)
Inventor
Assunta Imperato
Saliha Moussaoui
Carmen Obinu
Olivier Gobbo
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Priority to AU49514/97A priority Critical patent/AU4951497A/en
Publication of WO1998018465A1 publication Critical patent/WO1998018465A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine

Definitions

  • the present invention relates to the application of active principles endowed with an antagonistic activity of substance P and capable of crossing the blood-brain barrier, for the preparation of a medicament intended for the treatment of dyskines and related to diseases of the nervous system central and in particular late dyskinesias.
  • Dyskinesias are a syndrome that results in impaired movement such as involuntary movements of the limbs, tongue, lips or neck [Baldessarim, The Pharmacological bas s 10 of Therapeutics, 8th edition (1990), section 3 [Drugs and the Treatment of Psychiatry Disorders], Chap 18, 383-435, Goodman and Gilman's, Pergamon press].
  • dyskinesias due to the use of most of the neuroleptic drugs which appear neurological side effects which have been described in more detail by Baldessarim et al., Ara. J. Psychiatry, 137, 1163-1172 (1980) and by Latimer, Can. J. Psychiatry 40, 2suppl, 49S-54S (1995).
  • tardive dyskmesis is a syndrome which appears after prolonged treatment, of several months or several years, by neuroleptics and which results in impaired movements. These effects disappear by re-administration of the neuroleptic agent. There is currently no other form of treatment for these conditions.
  • Substance P antagonists are described for their activity in many conditions, including central nervous system conditions, but these active substances have never been shown to have an effect on the treatment of disease-related dyskinesias of the central nervous system and nothing
  • substance P antagonists which cross the blood brain barrier are capable of treating dyskinesias linked to diseases of the central nervous system.
  • the present invention relates to the application of these products to the preparation of a medicament intended for the treatment of these conditions as well as to the compositions which contain these active principles.
  • antagonists of substance P which cross the blood-brain barrier may be mentioned by way of example the products of the class of derivatives of 1,2-diamino ethane or of 1-acylamino-2-amino ethane, receptor antagonists.
  • non-peptidic tachykinins of the perhydroisoindole class, of the 3-amino-quinuclidin-2-substituted class, of the 2,3-disubstituted piperidin class, of the 3-amino-piperidin-2-substituted class , from the class of trisubstituted morpholine derivatives, from the class of substituted aromatic derivatives, from the class of quaternary salts of substituted piperidines, or of quaternary basic amides.
  • R is phenyl, indolyl-2 or -3, indolinyl-2 or -3, benzothienyl, benzofuranyl or naphthyl, these rings being optionally substituted by one or two halogen, (1-3C) alkyl, trifluoromethyl, (1-4C) alkyl , phenylalkoyl (1 -3C) oxy or alkanoyl (1-4.C);
  • R 1 is trityl, phenyl, diphenylmethyl, phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, hexamethyleneiminyl, benzofuranyl, tetrahy- dropyridinyl, quinolyl, isoquinolyl, isoquinolyl, isoquinolyl, isoquinolyl , isoquinolyl , phenylalkyl (1-4C), phenylalkyloxy (1-4C), quinolylalkyl (1-4C), isoquinolylalkyl (1-4C), quinolylalkyl (1-4C) saturated, isoquinolylalkyl (1-4C) saturated, benzoylalkyl -3C), (1-4C) alkyl or -NH-CH2 ⁇ R ⁇ , the radicals R 1 above can
  • R ' is also amino, a leaving group (group of atoms which is displaced from the carbon atom by attack by a nucleophile in a nucleophilic substitution reaction), a hydrogen atom, alkylamino (1 -4C) or dialkoylamino (alkyl: 1 -4C);
  • R- > is pyridyl, anilinoalkyl (1 -3C) or anilinocarbonyl;
  • R 2 is hydrogen, alkyl (1-4C), alkylsulfonyl (1-4C), carboxyalkyl (alkyl: 1-3C), alkyloxycarbonylalkyl (alkyl: 1-3C) or -CO-R 6 ;
  • R ° is hydrogen, alkyl (1-4C), haloalkyl (1-3C), phenyl, alkyloxy (1-3C), hydroxyalkyl (1-3C), amino, alkyllamino (1-4C), dialkoylamino (alkyl: 1 - 4C) or - (CH 2 ) qR 7 ; q is 0 to 3;
  • R 7 is carboxy, alkyloxycarbonyl (alkyl: 1-4C), alkylcarbonyloxy (alkyl: 1-4C), amino, alkylamino (1-4C), dialcoylamino (alkyl: 1-4C), alkyloycarbonylamino (alkyl: 1-6C ), phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, benzofuranyl, quinolyl, iso-quinolyl, saturated quinolyl, saturated isoquinolyl, phenylalkyl (1-4C), quinolylalkyl (1-4C) 1-4C), quinolylalkyl (1-4C) saturated, isoquinolylalkyl (1-4C) saturated, benzoylalkoyl (1-3C);
  • R 7 aryl or heterocyclyl can be substituted by halogen, trifluoromethyl, alkyloxy (1-4C), alkyl (1-4C), amino, alkylamino (1-4C), dialkoylamino (alkyl: 1-4C) or alkanoylamino (2-4C) and
  • R 7 groups may be substituted by phenyl, piperazinyl, c / cloalkyl (3-8C), benzyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, alkanoyl (2-6C) or alkoxycarbonyl (1-4C) - which can in turn be substituted by halogen, trifluoromethyl, amino, alkyloxy (1-4C), alkyl (1-4C), alkylamino (1-4C), dialcoylamino (alkyl: 1-4C) or alkanoylamino (2-4C) );
  • R ° is hydrogen or alkyl (1-6C);
  • R- is hydrogen, phenyl, phenylalkyl (1-6C), cycloalkyl (3-8C), cycloalkenyl (5-8C), alkyl (1-8C), naphthyl or alkenyl (2-8C) by one or two halogen, alkyl (1-3C), alkylthio (1-3C), nitro, trifluoromethyl or alkyl (1-3C) and
  • R 4 is hydrogen or alkyl (1-3C);
  • R 1 is hydrogen or halogen
  • R ⁇ is phenyl, phenylalkyl (1-6C), cycloalkyl (3-8C), cycloalkenyl (5-8C) or naphthyl, the alkyl radicals being straight or branched chain.
  • R represents a phenyl radical optionally substituted by one or more halogen atoms or hydroxy, alkyl radicals which can be optionally substituted (by halogen atoms or amino, alkylamino or dialkoylamino radicals) alkyloxy or alkylthio which can be optionally substituted [by hydroxy, amino, alkylamino or dialkoylamino radicals optionally substituted (by phenyl, hydroxy or amino radicals), or dialkoylamino, the alkyl parts of which form, with the nitrogen atom to which they are attached, a heterocycle at 5 to 6 links which may contain another heteroatom chosen from oxygen, sulfur (or nitrogen, optionally substituted by an alkyl, hydroxy or hydroxyalkyl radical), or substituted by amino, alkylamino or dialkylamino radicals, the parts of which alkyl can form with the nitrogen atom to which they are attached, a heterocycle as defined above, or represents a saturated or ms
  • R 2 represents a hydrogen or halogen atom or a hydroxy radical, alkyl, ammoalkyl, alkylammoalkyl, alkylammoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, alkyloxycarbonyl, dialkylammoalkylcarbonylcarbonylammoyalkylcarbonyl
  • X represents an oxygen or sulfur atom or a NRg radical for which Rg is a hydrogen atom, an alkyl radical containing 1 to 12 carbon atoms and optionally substituted [by one or more carboxy, dialkoylamino radicals, acylammo, alkyloxycarbonyl, alkyloxycarbonylammo, carbamoyl, alkylcarbamoyl, dialcoylcarbamoyl (the alkyl portions of these substituents can themselves be substituted by dialkoylamino or phenyl) or substituted by phenyl, substituted phenyl, alkyloyl, alkyl, alkyl, alkyl , thienyl, furyl, pyridyl or imidazolyl] or a dialkoylamino radical, or else if the ring has the formula (Ilb) or (Ile) the symbol X represents an oxygen atom, or an NH radical, or else
  • R are identical and represent phenyl radicals optionally substituted by a halogen atom or by a methyl radical in position 2 or 3,
  • R3 represents a halogen atom or a hydroxy radical and the symbol R4 represents a hydrogen atom or simultaneously with R3 represents a halogen atom.
  • R'3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical (1 or 2 carbon atoms)
  • the symbol R ' 4 represents a fluorine atom or a hydroxy radical
  • the symbol R5 represents a hydrogen atom or the symbols R'4 and R5 represent hydroxy radicals, or the symbol R'4 forms with R5 a bond.
  • the symbol R "3 represents a hydrogen atom and the symbol R" 4 represents a fluorine atom or a hydroxy radical, or else the symbol R "3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical (1 or 2 carbon atoms), and the symbol R "4 is a hydroxy radical, or else the symbols R" 3 and R "together form an oxo radical.
  • n is an integer from 0 to 2;
  • the products of general formula (IIa), (Ilb) and (Ile) can have stereoisomeric forms which are described in more detail in European patent applications EP 429 366, EP 514 273 and EP 514 275; that the products of general formula (Ild) are in the form (3aS, 4S, 7aS) or (3aRS, 4RS, 7aRS) or mixtures of these forms, if R4 is hydroxy or fluorine and R5 is hydrogen, or are present in the form (3aS, 4S, 5S, 7aS) or (3aRS, 4RS, 5RS, 7aRS) or mixtures of these forms, if R4 and R are hydroxy, or are in the form (3aS, 7aR) or (3aRS , 7aSR) or mixtures of these forms, if R4 forms a bond with R5; and that the products of general formula (Ile) are in the form (3aS, 7R, 7aR), (3aR, 7S, 7aS) or (3a
  • R3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical containing 1 or 2 carbon atoms or by a fluorine atom, or disubst killed by trifluoromethyl radicals and the symbols R and R'5 are identical or different and one represents a hydrogen atom or a hydroxy or alkyl radical and the other a hydrogen atom or an alkyl radical, and
  • the symbol R4 represents a hydroxy radical, or else the symbol R4 represents a fluorine atom if the symbols R5 and R'5 represent a hydrogen atom or an alkyl radical, or else the symbol R4 forms with R a bond and,
  • Rg represents a hydrogen atom or an alkyl, hydroxy or hydroxyalkyl radical
  • R represent one a hydrogen atom, an alkyl radical, a hydroxy or hydroxyalkyl radical and the other a hydrogen atom, an alkyl, phenyl or hydroxyalkyl radical,
  • alkyl and acyl radicals mentioned are straight or branched and contain 1 to 4C (unless special mention), in racemic form, in stereoisomeric forms of structure:
  • R is cycloalkyl (5-7C), norbornyle, pyrrolyle, thienyle, pyridyle, dolyle, biphenyle, 2, 3-d ⁇ hydrobenzofuranyl, alcoyloxythienyl of which the alkyl part contains 1 to 3 carbon atoms, hydroxypyridyle, quinolyle, naphthyle / alaphyl / the alkyl part contains 1 to 3 carbon atoms, 2, 3-methylened ⁇ oxyphenyl or phenyl which may be substituted by 1 or 2 substituents chosen from cyano, nitro, amino, N-monoalkylammo, fluorine, chlorine, bromine, trifluoromethyl, alkyl, alkyloxy, allyloxy, hydroxy, carboxy, alkyloxycarbonyl, benzyloxycarbonyl, carboxybenzyloxy, alkyloxycarbonylbenzyloxy, carboxamido or N, N-d ⁇ alco
  • R 2 is an Ar-CHR'- radical for which
  • R ' is branched alkyl (3-4C), branched alkenyl (5-6C), cycloalkyl (5-7C), furyl, thienyl, pyridyl, mdolyle, biphenyl or phenyl which can be substituted by 1 or 2 substituents chosen from fluorine, chlorine , bromine, trifluoromethyl, alkyl, alkyloxy, carboxy, alkyloxycarbonyl, benzyloxycarbonyl, phenylalkyl, allyloxy or hydroxy,
  • Ar is a thienyl or phenyl radical which can be substituted with 1 or 2 substituents chosen from fluorine, chlorine, bromine, trifluoromethyl, alkyl or alkyloxy, and R3 is a hydrogen atom or an alkyl radical (1-4C) located in position 5,
  • radicals and alkyl portions are in a straight or branched chain and contain 1 to 3 carbon atoms.
  • R- is -X-CH 2 -R for which X is an oxygen or sulfur atom, and R is phenyl optionally substituted by 1 to 3 identical or different radicals chosen from alkyl, (2-6C) alkenyl, (2- 6C), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR ', -SR', -SOR ', -S0 2 R', -NR'R ", -NR'COR", -NR'C0 2 R " , -C0 2 R 'or -CONR'R "for which R' and R" identical or different represent hydrogen, alkyl, phenyl or trifluoromethyl,
  • R is phenyl, naphthyl, indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl, quinolyl, benzhydryl or benzyl all these radicals which may also be substituted by alkyl, alkyloxy, halogen or trifluoromethyl,
  • Y is - (CH 2 ) n - for which n equals 1 to 3, each carbon in this chain being able to be substituted by R3 and / or R R 3 and R 5 are independently H, halogen, -CH 2 OR °, alkyl, oxo, COOR °° or CONR ⁇ R 000 for which R ° is H, alkyl or phenyl, R °° is hydrogen or alkyl and R 000 is hydrogen or alkyl,
  • R 4 is H, COR °, COOR 00 , COCONR ⁇ R 000 , COCOOR 00 or alkyl optionally substituted by [COOR c C0NR o O o OR- OOO OH, CN, COR °, -NR 00 R 000 , C (N0H) NR oo R 000 , CONHphenylalkyl (alkyl 1 -4C), COCOOR 00 ,
  • radicals and alkyl parts mentioned above are in straight or branched or cyclic chain and contain from 1 to 6 carbon atoms;
  • X is (CH 2 ) n in which n is an integer from 1 to 6 and in which each of the CC single bonds can be replaced by a double bond and in which each carbon can be optionally substituted by R 8 ,
  • R 6 is hydrogen, straight or branched chain alkyl, cycloalkyl (3-7C) in which one of the carbons can be replaced by an atom nitrogen, sulfur or oxygen, R 6 may also be an aryl chosen from biphenyl, phenyl, phenylalkyl, benzhydryl, benzyl, indanyl and naphthyl or a heteroaryl chosen from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, quinolyl, these aryls and heteroaryls being optionally substituted by one or more halogen, nitro, alkyl (1-1 OC), mono or di or trifluoroalkyl (1-1 OC), alkyloxy (1 -1 OC), mono or di or trifluoroalkyloxy (1-1 OC), amino, hydroxyalkyl, alkyloxyal
  • R 7 represents hydrogen, phenyl or alkyl
  • R 6 and R 7 form together with the carbon atom to which they are attached a saturated carbocyclic having 3 to 7 carbon atoms and in which one of the carbon atoms can be optionally replaced by oxygen, sulfur or nitrogen,
  • R a and R 9 independently represent hydrogen, hydroxy, halogen, amino, oxo, nitrile, hydroxyalkyl, alkyloxyalkyl, dialkoylamino, haloalkyl, alkyloxy, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonylalkylcarbonyloxyalkyl mentioned for R 6 ,
  • Rio is NHCOR12, NHCH2R12, NHSO 2 R 12 or one of the radicals mentioned for R 6 , R 8 and R 9 ,
  • R11 is oxi ino or one of the radicals mentioned for R 6 , R e and R 9 ,
  • Ri2 is alkyl, hydrogen, phenylalkyl or phenyl optionally substituted by alkyl, m is an integer from 0 to 8, in which each of the CC single bonds can be replaced by a double bond or a triple bond and the carbons are optionally substituted by R,
  • is a radical -NH-CH 2 -R for which R represents a phenyl radical trisubstituted by radicals X- ⁇ to X3 for which X-
  • R represents -N (R °) CH 2 -R 00
  • R ° is hydrogen or alkyl (1-8C) optionally substituted with hydroxy, alkyloxy or fluorine
  • R 00 is cycloalkyl (3-7C) in which one of the carbons may be replaced by a nitrogen, sulfur or oxygen atom and optionally substituted by 1 or 2 substituents, an aryl chosen from phenyl, naphthyl, mdanyl or a heteroaryl chosen from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl , oxazolyle, isoxazolyle, triazolyle, tétrazolyle and quinolyle, the aryls and heteroaryl being optionally substituted by one or more substituents, the substituents of the cycloalkyl, aryls and heteroaryl being chosen among halogen, nitro, alkyl, alkyloxy, trifluoro
  • radicals and alkyl parts mentioned above are in a straight or branched or cyclic chain and contain from 1 to 6 carbon atoms);
  • R- is -NH-CH 2 -R for which R is aryl chosen from mdanyl, phenyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl and quinolyl; cycloalkyl (3-7C) in which one of the carbon atoms can be replaced by N, 0 or S and where the aryl and heteroaryl groups can optionally be substituted by 1 or more substituents and the cycloalkyl radical can be optionally substituted with 1 or 2 substituents, these substituents being independently chosen from chlorine, fluorine, bromine, iodine, nitro, amino, alkylthio (1 to 10C), alkylsulfmyl (1-10C), alkylsulfonyl (1-10C), phenyl, phenoxy , 10C alkyl) suifonylammo, alkyl (1- 1 OC) sulfonylam oalkyl (1 -1 OC
  • R 2 represents thienyl, benzhydryl, naphthyl or phenyl optionally substituted with 1 to 3 substituents chosen from chlorine, fluorine, bromine, iodine, cycloalkyloxy (3-7C), alkyl (1-10C) optionally substituted with 1 to 3 fluorine atoms or alkyloxy (1-1 OC) optionally substituted with 1 to 3 fluorine atoms;
  • R- is 3,5- bis (trifluoromethyl) benzyloxy
  • R 2 is phenyl
  • R3 is (5-oxo-1H, 4H-1,2, 4-tr ⁇ azolo) methyl.
  • R is Q-CH 2 - for which Q is phenyl, naphthyl, mdolyl, benzothiophenyl, benzofuranyl, benzyl or dazolyl, these different rings being optionally substituted by one or more alkyl, alkenyl (2-6C), alkynyl (2 -6C), halogen, cyano, nitro, trifluoromethyl, trifluorosilyl, ORa ', SRa', SORa ', S0 2 Ra', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb ' and the mdolyl which may be optionally substituted on nitrogen by alkyl, phenylalkyl, COORa 'or CONRa' Rb ',
  • and R 2 are independently H, alkyl which can be substituted (by OH, CN, CORa, COORa, CONRaRb, or NRaRb), CORa, COORa, CONRaRb, CONRaCOORb, SO 2 Ra or phenylalkyl (1 -4C) optionally substituted on phenyl by one or more alkyl, alkyloxy, halogen or trifluoromethyl,
  • Ra and Rb are independently H, (1-12C) alkyl, trifluoromethyl or phenyl optionally substituted by one or more alkyl, alkyloxy, halogen or trifluoromethyl,
  • R is H or alkyl
  • R 4 is hydrogen, alkyl or phenyl optionally substituted by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, cyano, N0 2 , CF3, trimethylsilyl, ORa ', SRa', SORa ', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb '
  • R 5 is phenyl optionally substituted with 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, cyano, NO 2 , CF3, trimethylsilyl, ORa ', SRa', SORa ', NRa'Rb' , NRa'CORb ', NRa'COORb', COORa 'or CONRa'Rb',
  • Ra 'and Rb' are independently H, alkyl, trifluoromethyl or phenyl
  • radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C.
  • R is Q-CH - for which Q is phenyl substituted by one or more halogens, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, (2-6C) alkenyl, alkynyl (2-6C), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa ', SRa', SORa ', S0 2 Ra', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa 'Rb' and indolyl which may be optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa 'or CONRa'Rb',
  • and R 2 are independently H, alkyl which can be substituted (by OH, CN, CORa, COORa, CONRaRb, or NRaRb), CORa, COORa, CONRaRb, CONRaCOORb, COalcoylNRaRb, S0Ra or phenylalkyl (1 -4C) optionally substituted on phenyl by one or more alkyl, alkyloxy, halogen or trifluoromethyl,
  • Ra and Rb are independently H, alkyl (1 -12C), phenyl optionally substituted by alkyl, alkyloxy, halogen or trifluoromethyl or phenylalkyl (1 -4C) optionally substituted on phenyl by alkyl, alkyloxy, halogen or trifluoromethyl
  • R 3 is hydrogen, alkyl, alkenyl (2-6C),
  • R ' is phenyl optionally substituted by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, cyano, NO 2 , CF3, trimethylsilyl, ORa', SRa ', SORa', NRa'Rb ' , NRa'CORb ', NRa'COORb', COORa 'or CONRa'Rb'
  • Ra 'and Rb' are independently H, alkyl, trifluoromethyl or phenyl,
  • radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C
  • R is Q-CH 2 - for which Q is phenyl substituted by one or more halogen, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, alkenyl (2-6C) , (2-6C) alkynyl, halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa ', SRa', SORa ', S0 2 Ra', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb 'and 1 dolyle which may be optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa 'or CONRa'Rb',
  • Ri is hydrogen or alkyl
  • R3 is hydrogen, alkyl or alkenyl (2-6C),
  • R ' is phenyl which can be substituted on the ring by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, CN, NO 2 , CF3, trimethylsilyl, ORa', SRa ', SORa' groups , NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb ',
  • Ra 'and Rb' are independently H, alkyl, trifluoromethyl or phenyl,
  • radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C
  • R is Q-CH - for which Q is phenyl substituted by one or more halogen, naphthyl, mdolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, (2-6C) alkenyl, alkynyl (2-6C), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa, SRa, SORa, S0 2 Ra, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb and the mdolyle for before being optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa or CONRaRb,
  • Ri is hydrogen or alkyl
  • R 3 is hydrogen, alkyl or alkenyl (2-6C),
  • R ' is phenyl optionally substituted on the ring by 1 to 3 alkyl groups, alkenyl -2-6C), alkynyl (2-6C), halogen, CN, NO 2 , CF 3 , trimethylsilyl, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb in which Ra and Rb are Ra and Rb can be H, alkyl, phenyl or trifluoromethyl,
  • Ra and Rb are H, alkyl, phenyl or trifluoromethyl
  • radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C 5) either R is Q-CH 2 - for which Q is phenyl substituted by one or more halogen, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, alkenyl (2-6C) , (2-6C) alkynyl, halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa, SRa, SORa, S0 2 Ra, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb and indolyl which can be optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa or CONRaRb,
  • R-i is hydrogen or alkyl
  • R 2 is a group -CO-Z 'for which Z' is -alkyl-COOH, phenyl, phenylalkyl where each phenyl group is substituted by carboxy;
  • R 3 is hydrogen, alkyl or alkenyl (2-6C),
  • R ' is phenyl optionally substituted on the ring with 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, CN, NO 2 , CF 3 , trimethylsilyl, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb,
  • Ra and Rb are independently H, alkyl, phenyl or trifluoromethyl
  • radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C
  • R is Q-CH 2 - for which Q is phenyl substituted by one or more halogen, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, alkenyl (2-6C) , (2-6C) alkynyl, halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa, SRa, SORa, S0 2 Ra, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb and indolyl for before being optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa or CONRaRb,
  • R-i is hydrogen or alkyl
  • R 2 is a group -CO-Z 'for which Z' is -alkyl-COOH, phenyl, phenylalkyl where each phenyl group is substituted by carboxy;
  • R 3 is hydrogen, alkyl or alkenyl (2-6C),
  • X and Y together form an oxo radical and -ZR 'represents a radical -NR4 ⁇ CH 2 R' for which R 'is phenyl optionally substituted by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C) groups , halogen, CN, N0 2 , CF 3 , trimethylsilyl, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb in which Ra and Rb are H, alkyl, phenyl or trifluoromethyl, and R4 is H or alkyl and
  • R 2 is a group -CO-X2-Y2-R 6 , X 2 is a bond, O, S, NH or Nalcoyl, Y 2 is a bond or alkylidene (1-6C) and R 6 is NRcRd or an azacyclic group aromatic or non-aromatic or a_.
  • Ra and Rb are independently H, alkyl, phenyl or trifluoromethyl
  • Rc and Rd are independently hydrogen, alkyl, phenyl optionally substituted by alkyl, alkyloxy, halogen or trifluoromethyl or phenylalkyl optionally substituted by alkyl, alkyloxy, halogen or trifluoromethyl,
  • radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C.
  • a ⁇ is an anion and, in particular, Cl-, Br-, I ⁇ , acetate, methane-sulfonate, p. toluenesulfonate,
  • n 2 or 3
  • Ar ' is thienyl, benzothienyl, naphthyl, indolyl, N-alkyl (1-4C) indolyl, phenyl optionally mono or poly substituted by halogen, trifluoromethyle, alkyl (1-4C), alkyloxy (1-4C), OH or trifluoromethyl) ,
  • R is hydrogen or alkyl (1-6C),
  • T is CO or CONH or CSNH
  • Z is either H, M or OM when T is CO, or M when T is CONH or CSNH
  • M is alkyl (1-6C), pyridylalkyl (1 -3C), naphthylalkyl (1-3C) optionally substituted on the naphthyl by halogen, trifluoromethyle, alkyl (1-4C), hydroxy or alkyloxy (1-4C), pyridylthioalkyl ( 1-3C), styryl, phenylalkyl (1 -3C) optionally substituted on the phenyl by one or more halogen, trifluoromethyl, alkyl (1-4C), hydroxy oualkyloxy (1-4C), an aromatic group mono, di or tricyclic optionally substituted or heteroaromatic mono, di or tricyclic can carry one or more substituents in which a carbon atom of the aromatic carbocycle or of the aromatic heterocycle is directly linked to the group T or a benzyl group optionally substituted on the aromatic
  • Z is an aromatic
  • this may for example be phenyl optionally substituted, naphthyl optionally substituted by [one or more halogen, (1-4C) alkyl, phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, oxo, alkyl ( 1-4C) carbonylammo, alkyloxy-4C) carbonyl, thioalkyl (1-4C)], benzyl optionally substituted by one or more halogen, trifluoromethyl, alkyl (1-4C), alkyloxy (1-4C) or hydroxy.
  • Z is a phenyl
  • this can be substituted by one or more halogen, OH, amino, NHCONH 2 , nitro, CONH 2 , trifluoromethyl, alkyl (1-10C), alkenyl (2-10C), alkynyl (2 -10C), cycloalkyl (3-8C), bicycloalkyl (4-11C), hydroxyalkyl (1-5C), alkyloxy (1-10C), alkyloxyalkyl (2-10C), alkylalkyloyloxy (3-1 OC), alkyloxyalkyloyloxy (2 -1 OC), alkenyloxy (2-10C), alkenyloxyalkyl (2-10C), alkynyloxyalkyl (3-10C), cycloalcoyloxy (3-8C), alkylthio (1-10C), alkylthioalkyl (2-10C), acylammo (1-7C), aroylam o, benzylammo, acylammoalkyl (2
  • Z When Z is a heteroaromatic it can be pyridyl, thiazidolyl, indolyl, mdazolyl, imidazolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzisothiazolyl, quinolyl, isoquimolyl, benzoxazolyl îsoxazolyl, benzopyranyl, thiazolyl, thienyl, furyl, pyranyl, chromenyl, isobenzofuranyl, pyrrolyl, pyrazolyl, pyrazmyl, pyrimidinyl, pyridazinyl, indolizinyl, phthalazmyl, qu azolinyl, acridmyl, isidiazylyl, isothiazolyl, isothiazolyl may be hydrogenated, these heteroaromatics being optionally
  • A- is an anion
  • Ar is a mono, di or tricyclic aromatic or heteroaromatic which can carry one or more substituents, of which a carbon atom of the carbocycle or of the aromatic heterocycle is directly linked to T,
  • Ar ' is thienyl, benzothienyl, naphthyl, mdolyl or phenyl, optionally ent mono or poly substituted by halogen, trifluoromethyl, alkyl (1-4C) or alkyloxy (1-3C),
  • T is a direct bond, a hydroxymethylene, alkyloxyethylene (1-4C) or alkylene (1-5C) group,
  • Z is an optionally substituted mono, di, or tricyclic aromatic or heteroaromatic group
  • Q is hydrogen and R is and H, alkyl (1-4C), ⁇ -alkyloxy (1 - 4C) alkyl (2-4C), ⁇ -alkanoyloxy (2-4C) alkyl (2-4C),
  • R and Q form a group 1, 2-ethylene, 1, 3-propylene or 1,4-butylene.
  • Ar is an aromatic
  • this may for example be phenyl optionally substituted, naphthyl optionally substituted by [one or more halogen, (1-4C) alkyl, phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, alkyloxy (1- 4C), oxo, alkyl (1-4C) carbonylammo, alkyloxy (1-4C) carbonyl, thioalkyl (1-4C)], mdenyl one or more bonds of which can be hydrogenated and optionally substituted by [one or more halogen, alkyl ( 1-4C), phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, alkyloxy (1-4C), oxo, alkyl (1-4C) carbonylammo, alkyloxy (1-4C) carbonyl, thioalkyl (1-4C)] .
  • Ar is a phenyl
  • this can be substituted by one or more halogen, 011, amino, NHC0NH 2 , nitro, C0NH 2 , trifluoromethyle, alkyl (1-10C), alkenyl (2-10C), alkynyl (2 -10C), cycloalkyl (3-8C), bicycloalkyl (4-11C), hydroxyalkyl (1-5C), alkyloxy (1-10C), alkyloxyalkyl (2-10C), alkylalkyloyloxy (3-1 OC), alkyloxyalkyloyloxy (2 -1 OC), alkenyloxy (2-1 OC), alkenyloxyalkyl (2-10C), alkynyloxyalkyl (3-10C), cycloalkyloxy (3-8C), alkylthio (1-1 OC), alkylthioalkyl (2-10C) , acylammo (1-7C), aroylamino, benzylammo, acylammo (1
  • Ar When Ar is a heteroaromatic, it can be pyridyl, thiazidolyl, indolyl, indazolyl, imidazolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzisothiazolol, quinolyl, issoqumolyl, benzidazolyl, benzoxazolyl yl, isoxazolyl, benzopyranyl, thiazolyl, thienyl, furyl, pyranyl, chromenyl, isobenzofuranyl, pyrrolyl, pyrazolyle, pyrazmyle, pyrimidmyle, pyridazmyle, mdolizinyl, phthalazmyl, qumazolmyl, isylamyl, isylazyl, isidiazyl bonds can be hydrogenated, these heteroaromatic
  • substance P antagonists which cross the blood-brain barrier, in the treatment of dyskinesias has been demonstrated in the model of dyskinesias induced by haloperidol in rats:
  • the decanoate form of haloperidol is capable of inducing in rats from the 4th week after infection, a large number of buccolinguinal movements (very similar to dyskinetic movements occurring in humans following chronic administration of neuroleptics).
  • Maize Sprague-Dawley rats weighing 200-220 g are kept for at least 5 days before use.
  • the rats are grouped in groups of 3, with free access to food and water. In the morning of the experience, food and water are removed for the duration of the experience.
  • haloperidol decanoate 40 mg / kg of haloperidol decanoate (0.8 ml / kg) are injected into the animals by intramuscular route to induce orofacial dyskinesia. (Jorgensen et al., Psychopharmacol., 116, 89 (1994). The control animals receive an equivalent volume of vehicle used for haloperidol.
  • Dyskinetic behavior characterized by abnormal involuntary buccolingual movements is measured by counting the number of chews during 2 periods of 30 minutes of observation each: one preceding the administration of the molecule to be tested and the other 30 minutes after the administration of this molecule. The measurements are compared.
  • An active product is a product which significantly reduces the number of involuntary movements evaluated after its administration compared to the number of involuntary movements evaluated before its administration.
  • the present invention also relates to the preparation of pharmaceutical compositions comprising a substance P antagonist capable of crossing the blood-brain barrier, in the pure state or in the form of a combination with one or more compatible and pharmaceutically acceptable diluents and / or adjuvants and / or optionally in combination with any other physiologically active pharmaceutically compatible product, intended for the treatment of dyskinesias linked to diseases of the central nervous system.
  • compositions prepared according to the invention can be used parenterally, orally, rectally, transdermally and aerosols.
  • the sterile compositions for parenteral administration which can in particular be used in the form of infusions are preferably aqueous or non-aqueous solutions, suspensions or emulsions.
  • solvent or vehicle it is possible to use water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or the like. suitable organic solvents.
  • These compositions can also contain adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. Sterilization can be done in several ways, by for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in a sterile injectable medium.
  • compositions for rectal administration are suppositories or rectal capsules, which contain, in addition to the active product, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
  • compositions for oral administration can be capsules, tablets, pills, powders or granules.
  • the active principle (optionally associated with another pharmaceutically compatible product) is mixed with one or more inert diluents or adjuvants, such as sucrose, lactose or starch.
  • these compositions can also include substances other than diluents, for example a lubricant such as magnesium stearate.
  • the liquid compositions for oral administration can be pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents such as water or paraffin oil. These compositions can also include substances other than diluents, for example wetting, sweetening or flavoring products.
  • compositions for topical administration can be, for example, creams, ointments, or lotions.
  • compositions can also be aerosols.
  • the compositions can be stable sterile solutions or solid compositions dissolved at the time of use in sterile pyrogen-free water, serum or any other pharmaceutically acceptable vehicle.
  • the active principle is finely divided and associated with a diluent or vehicle water-soluble liquid with a particle size of 30 to 80 ⁇ m, for example dextran, mannitol or lactose.
  • the doctor will determine the dosage he considers most appropriate based on age, weight and all other factors specific to the subject to be treated.
  • the doses depend on the desired effect and on the duration of the treatment. For an adult, they are generally between 0.25 and 2500 mg per day in staggered doses.
  • composition prepared according to the invention and intended for the treatment of dyskinesias.
  • Active product tablets having the following composition are prepared according to the usual technique:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention concerns the use of active principles having an activity antagonist of the substance P, capable of passing through the hematoencephalic barrier, for preparing a medicine for the treatment of diskinesia linked with diseases of the central nervous system.

Description

UTILISATION DES ANTAGONISTES DE LA SUBSTANCE P POUR LE TRAITEMENT DES DYSKINESIES TARDIVESUSE OF ANTAGONISTS OF SUBSTANCE P FOR THE TREATMENT OF LATE DYSKINESIA
La présente invention concerne l'application de principes actifs doués d'une activité antagoniste de la substance P et capables de passer la barrière hématoencéphalique , pour la préparation d'un médi- 5 cament destiné au traitement des dyskinés es liées aux maladies du système nerveux central et notamment des dyskinésies tardives.The present invention relates to the application of active principles endowed with an antagonistic activity of substance P and capable of crossing the blood-brain barrier, for the preparation of a medicament intended for the treatment of dyskines and related to diseases of the nervous system central and in particular late dyskinesias.
Les dyskinésies sont un syndrome qui entraîne une altération des mouvements telle que des mouvements involontaires des membres, de la langue, des lèvres ou du cou [Baldessarim, The Pharmacological bas s 10 of Therapeutics, 8th édition (1990), section 3 [Drugs and the Treatment of Psychiatrie Disorders] , Chap 18, 383-435, Goodman and Gil- man's, Pergamon press] .Dyskinesias are a syndrome that results in impaired movement such as involuntary movements of the limbs, tongue, lips or neck [Baldessarim, The Pharmacological bas s 10 of Therapeutics, 8th edition (1990), section 3 [Drugs and the Treatment of Psychiatry Disorders], Chap 18, 383-435, Goodman and Gilman's, Pergamon press].
Les causes de dyskinésies chez l'homme sont nombreuses et diverses. Un exemple est celui des dyskinésies dues à l'usage de la plupart des 15 médicaments neuroleptiques qu fait apparaître des effets secondaires neurologiques qui ont été décrits plus en détail par Baldessarim et coll., Ara. J. Psychiatry, 137, 1163-1172 (1980) et par Latimer, Can. J. Psychiatry 40, 2suppl, 49S-54S (1995).The causes of dyskinesias in humans are many and diverse. An example is that of dyskinesias due to the use of most of the neuroleptic drugs which appear neurological side effects which have been described in more detail by Baldessarim et al., Ara. J. Psychiatry, 137, 1163-1172 (1980) and by Latimer, Can. J. Psychiatry 40, 2suppl, 49S-54S (1995).
Parmi ces effets secondaires la dyskmésie tardive est un syndrome 20 qui apparaît après un traitement prolongé, de plusieurs mois ou plusieurs années, par les neuroleptiques et qui entraîne une altération des mouvements. Ces effets disparaissent par réadministration de l'agent neuroleptique. Il n'existe pas actuellement d'autre forme de traitement de ces affections.Among these side effects, tardive dyskmesis is a syndrome which appears after prolonged treatment, of several months or several years, by neuroleptics and which results in impaired movements. These effects disappear by re-administration of the neuroleptic agent. There is currently no other form of treatment for these conditions.
25 Des antagonistes de la substance P sont décrits pour leur activité dans de nombreuses affections, parmi lesquelles des affections du système nerveux central, mais il n'avait ïamais été démontré que ces principes actifs pouvaient avoir un effet sur le traitement des dyskinésies liées aux maladies du système nerveux central et rien ne25 Substance P antagonists are described for their activity in many conditions, including central nervous system conditions, but these active substances have never been shown to have an effect on the treatment of disease-related dyskinesias of the central nervous system and nothing
30 pouvait laisser le supposer. Il a maintenant été trouvé et c'est ce qui fait l'objet de la présente invention, que les antagonistes de la substance P qui traversent la barrière hématoencéphalique sont capables de traiter les dyskinésies liées aux maladies du système nerveux central.30 could suggest. It has now been found, and this is the subject of the present invention, that substance P antagonists which cross the blood brain barrier are capable of treating dyskinesias linked to diseases of the central nervous system.
La présente invention concerne l'application de ces produits à la préparation d'un médicament destiné au traitement de ces affections ainsi que les compositions qui contiennent ces principes actifs.The present invention relates to the application of these products to the preparation of a medicament intended for the treatment of these conditions as well as to the compositions which contain these active principles.
Parmi les antagonistes de la substance P qui traversent la barrière hématoencéphalique peuvent être cités à titre d'exemple les produits de la classe des dérivés du diamino-1,2 éthane ou de 1 ' acylamino- 1 amino-2 éthane, antagonistes des récepteurs à tachykinines non pep- tidiques, de la classe des perhydroisoindoles , de la classe des 3- amino-quinuclidines-2-substituées, de la classe des pipéridines 2,3- disubstituées, de la classe des 3-amino-pipéridines-2-substituées, de la classe des dérivés trisubstitués de la morpholine, de la classe des dérivés aromatiques substitués, de la classe des sels quaternaires de pipéridines substituées, ou des amides basiques quaternaires.Among the antagonists of substance P which cross the blood-brain barrier may be mentioned by way of example the products of the class of derivatives of 1,2-diamino ethane or of 1-acylamino-2-amino ethane, receptor antagonists. non-peptidic tachykinins, of the perhydroisoindole class, of the 3-amino-quinuclidin-2-substituted class, of the 2,3-disubstituted piperidin class, of the 3-amino-piperidin-2-substituted class , from the class of trisubstituted morpholine derivatives, from the class of substituted aromatic derivatives, from the class of quaternary salts of substituted piperidines, or of quaternary basic amides.
Plus particulièrement parmi les produits de la classe des dérivés du diamino-1,2 éthane ou de 1 'acylamino-1 amino-2 éthane, antagonistes de la substance P (antagonistes des récepteurs à tachykinines) non peptidiques, on peut citer ceux de formule générale :More particularly, among the products of the class of derivatives of 1,2-diamino ethane or 1-acylamino-2 amino-2 ethane, antagonists of substance P (non-tachykinin receptor antagonists), mention may be made of those of formula general:
R8 R4R 8 R 4
I ιI ι
R—(CH2)n—C-CH2—N— (CH^-R-* (DR— (CH 2 ) n —C-CH 2 —N— (CH ^ -R- * (D
NH R2NH R 2
Figure imgf000004_0001
Figure imgf000004_0001
R1 R 1
dans laquelle m est 0, 1, 2 ou 3; n est 0 ou 1 ; o est 0, 1 ou 2 ; p est 0 ou 1 , R est phényle, indolyle-2 ou -3, indolinyle-2 ou -3, benzothiényle, benzofuranyle ou naphtyle, ces cycles étant éventuellement substitués par un ou deux halogène, alcoyloxy (1-3C), trifluoromethyle, alcoyle (1-4C), phénylalcoyl (1 -3C)oxy ou alcanoyle (1-4.C);where m is 0, 1, 2 or 3; n is 0 or 1; o is 0, 1 or 2; p is 0 or 1, R is phenyl, indolyl-2 or -3, indolinyl-2 or -3, benzothienyl, benzofuranyl or naphthyl, these rings being optionally substituted by one or two halogen, (1-3C) alkyl, trifluoromethyl, (1-4C) alkyl , phenylalkoyl (1 -3C) oxy or alkanoyl (1-4.C);
R1 est trityle, phényle, diphénylméthyle, phénoxy, phénylthio, pipé- razinyle, pipéridinyle, pyrrolidinyle , morpholinyle, indolinyle, in- dolyle, benzothiényle, hexaméthylèneiminyle , benzofuranyle, tétrahy- dropyridinyle , quinolyle, isoquinolyle, quinolyle saturé, isoquino- lyle saturé, phénylalcoyle (1 -4C) , phénylalcoyloxy (1 -4C) , quinolylal- coyle(1-4C), isoquinolylalcoyle (1 -4C) , quinolylalcoyle (1 -4C) saturé, isoquinolylalcoyle (1 -4C) saturé, benzoylalcoyle (1 -3C) , alcoyle (1-4C) ou -NH-CH2~R^, les radicaux R1 ci-dessus pouvant être substitués par halogène, alcoyle (1-4C), alcoyloxy (1-4C), trifluoromethyle, amino, alcoylamino (1-4C), dialcoylamino (alcoyle : 1-4C) ou alcanoylamino (2-4C) , ou bien les radicaux R1 pouvant être substitués par phényle, pipérazinyle, cycloalcoyle (3-8C) , benzyle, alcoyle (1-4C), pipéridinyle, pyridinyle, pyrimidinyle, alcanoylamino (2-6C) , pyrrolidinyle, alcanoyle (2-6C) ou alcoyloxycarbonyle (alcoyle : 1 -4C) , eux mêmes pouvant être substitués par halogène, alcoyle (1-4C), alcoyloxy (1- 4C) , trifluoromethyle, amino, alcoylamino (1-4C), dialcoylamino (alcoyle : 1-4C) ou alcanoylamino (2-4C) ; ou bienR 1 is trityl, phenyl, diphenylmethyl, phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, hexamethyleneiminyl, benzofuranyl, tetrahy- dropyridinyl, quinolyl, isoquinolyl, isoquinolyl, isoquinolyl , phenylalkyl (1-4C), phenylalkyloxy (1-4C), quinolylalkyl (1-4C), isoquinolylalkyl (1-4C), quinolylalkyl (1-4C) saturated, isoquinolylalkyl (1-4C) saturated, benzoylalkyl -3C), (1-4C) alkyl or -NH-CH2 ~ R ^, the radicals R 1 above can be substituted by halogen, alkyl (1-4C), alkyloxy (1-4C), trifluoromethyl, amino, alkyllamino (1-4C), dialcoylamino (alkyl: 1-4C) or alkanoylamino (2-4C), or the radicals R 1 which may be substituted by phenyl, piperazinyl, cycloalkyl (3-8C), benzyl, alkyl (1- 4C), piperidinyl, pyridinyl, pyrimidinyl, alkanoylamino (2-6C), pyrrolidinyl, alkanoyl (2-6C) or alkyloxycarbonyl (alkyl: 1-4C ), which themselves can be substituted by halogen, alkyl (1-4C), alkyloxy (1- 4C), trifluoromethyl, amino, alkylamino (1-4C), dialcoylamino (alkyl: 1-4C) or alkanoylamino (2-4C) ; or
R' est également amino, un groupe partant (groupe d'atomes qui est déplacé de l'atome de carbone par l'attaque d'un nucléophile dans une réaction de substitution nucléophile) , un atome d'hydrogène, alcoyla- mino (1-4C) ou dialcoylamino (alcoyle : 1 -4C) ;R 'is also amino, a leaving group (group of atoms which is displaced from the carbon atom by attack by a nucleophile in a nucleophilic substitution reaction), a hydrogen atom, alkylamino (1 -4C) or dialkoylamino (alkyl: 1 -4C);
R-> est pyridyle, anilinoalcoyle (1 -3C) ou anilinocarbonyle;R- > is pyridyl, anilinoalkyl (1 -3C) or anilinocarbonyl;
R2 est hydrogène, alcoyle (1-4C), alcoylsulfonyle (1-4C), carboxyal- coyle (alcoyle : 1-3C), alcoyloxycarbonylalcoyle (alcoyle : 1-3C) ou -CO-R6 ;R 2 is hydrogen, alkyl (1-4C), alkylsulfonyl (1-4C), carboxyalkyl (alkyl: 1-3C), alkyloxycarbonylalkyl (alkyl: 1-3C) or -CO-R 6 ;
R° est hydrogène, alcoyle (1-4C), haloalcoyle (1-3C), phényle, alcoyloxy (1-3C), hydroxyalcoyle (1-3C), amino, alcoylamino (1-4C), dialcoylamino (alcoyle : 1 -4C) ou -(CH2)q-R7; q est 0 à 3 ;R ° is hydrogen, alkyl (1-4C), haloalkyl (1-3C), phenyl, alkyloxy (1-3C), hydroxyalkyl (1-3C), amino, alkyllamino (1-4C), dialkoylamino (alkyl: 1 - 4C) or - (CH 2 ) qR 7 ; q is 0 to 3;
R7 est carboxy, alcoyloxycarbonyle (alcoyle : 1-4C), alcoylcarbony- loxy (alcoyle : 1-4C), amino, alcoylamino (1-4C), dialcoylamino (alcoyle : 1 -4C) , alcoyloxycarbonylamino (alcoyle : 1-6C), phénoxy, phénylthio, pipérazinyle, pipéridinyle, pyrrolidinyle, morpholinyle, indolinyle, indolyle, benzothiényle, benzofuranyle, quinolyle, iso- quinolyle, quinolyle saturé, isoquinolyle saturé, phénylalcoyle ( 1 - 4C) , quinolylalcoyle (1 -4C) , isoquinolylalcoyle (1 -4C) , quinolylal- coyle(1-4C) saturé, isoquinolylalcoyle (1 -4C) saturé, benzoylal- coyle(1-3C);R 7 is carboxy, alkyloxycarbonyl (alkyl: 1-4C), alkylcarbonyloxy (alkyl: 1-4C), amino, alkylamino (1-4C), dialcoylamino (alkyl: 1-4C), alkyloycarbonylamino (alkyl: 1-6C ), phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, benzofuranyl, quinolyl, iso-quinolyl, saturated quinolyl, saturated isoquinolyl, phenylalkyl (1-4C), quinolylalkyl (1-4C) 1-4C), quinolylalkyl (1-4C) saturated, isoquinolylalkyl (1-4C) saturated, benzoylalkoyl (1-3C);
étant entendu que tous les R7 aryle ou hétérocyclyle peuvent être substitués par halogène, trifluoromethyle, alcoyloxy (1-4C), alcoyle (1-4C), amino, alcoylamino (1-4C), dialcoylamino (alcoyle : 1-4C) ou alcanoylamino (2-4C) etit being understood that all of the R 7 aryl or heterocyclyl can be substituted by halogen, trifluoromethyl, alkyloxy (1-4C), alkyl (1-4C), amino, alkylamino (1-4C), dialkoylamino (alkyl: 1-4C) or alkanoylamino (2-4C) and
étant entendu que les groupes R7 peuvent être substitués par phényle, pipérazinyle, c/cloalcoyle (3-8C) , benzyle, pipéridinyle, pyridinyle, pyrimidinyle, pyrrolidinyle, alcanoyle (2-6C) ou alcoyloxycarbonyle (1-4C) chacun de ceux-ci pouvant être à leur tour substitués par halogène, trifluoromethyle, amino, alcoyloxy (1-4C), alcoyle (1-4C), alcoylamino (1-4C), dialcoylamino (alcoyle : 1-4C) ou alcanoylamino (2-4C) ;it being understood that the R 7 groups may be substituted by phenyl, piperazinyl, c / cloalkyl (3-8C), benzyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, alkanoyl (2-6C) or alkoxycarbonyl (1-4C) - which can in turn be substituted by halogen, trifluoromethyl, amino, alkyloxy (1-4C), alkyl (1-4C), alkylamino (1-4C), dialcoylamino (alkyl: 1-4C) or alkanoylamino (2-4C) );
R° est hydrogène ou alcoyle (1-6C);R ° is hydrogen or alkyl (1-6C);
R- est hydrogène, phényle, phénylalcoyle (1 -6C) , cycloalcoyle (3-8C) , cycloalcényle (5-8C) , alcoyle (1-8C), naphtyle ou alcényle (2-8C) , ceux-ci pouvant être substitués par un ou deux halogène, alcoyloxy (1-3C), alcoylthio (1-3C), nitro, trifluoromethyle ou alcoyle (1-3C) etR- is hydrogen, phenyl, phenylalkyl (1-6C), cycloalkyl (3-8C), cycloalkenyl (5-8C), alkyl (1-8C), naphthyl or alkenyl (2-8C) by one or two halogen, alkyl (1-3C), alkylthio (1-3C), nitro, trifluoromethyl or alkyl (1-3C) and
R4 est hydrogène ou alcoyle (1-3C);R 4 is hydrogen or alkyl (1-3C);
sous réserve que si R1 est hydrogène ou halogène, R^ est phényle, phénylalcoyle (1-6C), cycloalcoyle (3-8C) , cycloalcényle (5-8C) ou naphtyle, les radicaux alkyle étant à chaîne droite ou ramifiée.provided that if R 1 is hydrogen or halogen, R ^ is phenyl, phenylalkyl (1-6C), cycloalkyl (3-8C), cycloalkenyl (5-8C) or naphthyl, the alkyl radicals being straight or branched chain.
A titre d'exemple, parmi les produits de la classe des perhydroisom- doles on peut citer ceux de formule générale :By way of example, among the products of the perhydroisomedols class, mention may be made of those of general formula:
Figure imgf000007_0001
Figure imgf000007_0001
le symbole R représente un radical phényle éventuellement substitué par un ou plusieurs atomes d'halogène ou radicaux hydroxy, alcoyle pouvant être éventuellement substitués (par des atomes d'halogène ou des radicaux amino, alcoylamino ou dialcoylamino) alcoyloxy ou al- coylthio pouvant être éventuellement substitués [par des radicaux hydroxy, amino, alcoylamino ou dialcoylamino éventuellement substitués (par des radicaux phényle, hydroxy ou amino) , ou dialcoylamino dont les parties alcoyle forment avec l'atome d'azote auquel elles sont rattachées, un hétérocycle à 5 à 6 chaînons pouvant contenir un autre hétéroatome choisi parmi l'oxygène, le soufre ^u l'azote, éven- tuellement substitué par un radical alcoyle, hydroxy, hydroxyal- coyle) ] , ou substitué par des radicaux amino, alcoylamino, dialcoylamino dont les parties alcoyle peuvent former avec l'atome d'azote auquel elles sont rattachées, un hétérocycle tel que défini ci-dessus , ou représente un radical cyclohexadiènyle, naphtyle ou hétérocyclyle mono ou polycyclique, saturé ou msaturé (5 à 9 atomes de carbone) et un ou plusieurs hétéroatomes choisis parmi l'oxygène, l'azote ou le soufre, et éventuellement substitué par un atome d'halogène ou par un radical alcoyle ou alcoyloxy,the symbol R represents a phenyl radical optionally substituted by one or more halogen atoms or hydroxy, alkyl radicals which can be optionally substituted (by halogen atoms or amino, alkylamino or dialkoylamino radicals) alkyloxy or alkylthio which can be optionally substituted [by hydroxy, amino, alkylamino or dialkoylamino radicals optionally substituted (by phenyl, hydroxy or amino radicals), or dialkoylamino, the alkyl parts of which form, with the nitrogen atom to which they are attached, a heterocycle at 5 to 6 links which may contain another heteroatom chosen from oxygen, sulfur (or nitrogen, optionally substituted by an alkyl, hydroxy or hydroxyalkyl radical), or substituted by amino, alkylamino or dialkylamino radicals, the parts of which alkyl can form with the nitrogen atom to which they are attached, a heterocycle as defined above, or represents a saturated or msaturated cyclohexadienyl, naphthyl or heterocyclyl radical, mono or polycycllyl (5 to 9 carbon atoms) and one or more heteroatoms chosen from oxygen, nitrogen or sulfur, and optionally substituted by a halogen atom or by an alkyl or alkyloxy radical,
le symbole R2 représente un atome d'hydrogène ou d'halogène ou un radical hydroxy, alcoyle, ammoalcoyle, alcoylammoalcoyle , d alcoy- lammoalcoyle, alcoyloxy, alcoylthio, acyloxy, carboxy, alcoyloxycarbonyle, dialcoylammoalcoyloxycarbonyle, benzyloxycarbonyle, amino ou acylammo,the symbol R 2 represents a hydrogen or halogen atom or a hydroxy radical, alkyl, ammoalkyl, alkylammoalkyl, alkylammoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, alkyloxycarbonyl, dialkylammoalkylcarbonylcarbonylammoyalkylcarbonyl
le bicycle :
Figure imgf000008_0001
the bicycle:
Figure imgf000008_0001
représente un cycle perhydroisomdole ou thiapyranopyrrole de formule générale :represents a perhydroisomdole or thiapyranopyrrole cycle of general formula:
Figure imgf000008_0002
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000008_0003
et le symbole X représente un atome d'oxygène ou de soufre ou un radical NRg pour lequel Rg est un atome d'hydrogène, un radical alcoyle contenant 1 à 12 atomes de carbone et éventuellement substitué [par un ou plusieurs radicaux carboxy, dialcoylamino, acylammo, alcoyloxycarbonyle, alcoyloxycarbonylammo, carbamoyle, alcoylcarbamoyle, dialcoylcarbamoyle (les portions alcoyle de ces substituants pouvant être elles même substituées par dialcoylamino ou phényle) ou substitué par des radicaux phényle, phényle substitué (par halogène, alcoyle, alcoyloxy, ou dialcoylamino), naphtyle, thiènyle, furyle, py- ridyle ou îmidazolyle] ou un radical dialcoylamino, ou bien si le cycle est de formule (Ilb) ou (Ile) le symbole X représente un atome d'oxygène, ou un radical NH, ou bienand the symbol X represents an oxygen or sulfur atom or a NRg radical for which Rg is a hydrogen atom, an alkyl radical containing 1 to 12 carbon atoms and optionally substituted [by one or more carboxy, dialkoylamino radicals, acylammo, alkyloxycarbonyl, alkyloxycarbonylammo, carbamoyl, alkylcarbamoyl, dialcoylcarbamoyl (the alkyl portions of these substituents can themselves be substituted by dialkoylamino or phenyl) or substituted by phenyl, substituted phenyl, alkyloyl, alkyl, alkyl, alkyl , thienyl, furyl, pyridyl or imidazolyl] or a dialkoylamino radical, or else if the ring has the formula (Ilb) or (Ile) the symbol X represents an oxygen atom, or an NH radical, or else
le bicycle
Figure imgf000009_0001
the bicycle
Figure imgf000009_0001
représente un cycle perhydroisomdole ou thiapyranopyrrole de formule générale :represents a perhydroisomdole or thiapyranopyrrole cycle of general formula:
Figure imgf000009_0002
Figure imgf000009_0002
et le symbole X représente un atome d'oxygène.and the symbol X represents an oxygen atom.
Dans les formules générales (lia) à (Ile) :In the general formulas (lia) to (Ile):
les symboles R sont identiques et représentent des radicaux phényle éventuellement substitués par un atome d'halogène ou par un radical méthyle en position 2 ou 3,the symbols R are identical and represent phenyl radicals optionally substituted by a halogen atom or by a methyl radical in position 2 or 3,
les symboles R" sont identiques et représentent des atomes d'hydro- gène ou forment ensemble une liaison,the symbols R "are identical and represent hydrogen atoms or together form a bond,
le symbole R3 représente un atome d'halogène ou un radical hydroxy et le symbole R4 représente un atome d'hydrogène ou simultanément à R3 représente un atome d'halogène.the symbol R3 represents a halogen atom or a hydroxy radical and the symbol R4 represents a hydrogen atom or simultaneously with R3 represents a halogen atom.
le symbole R'3 représente un radical phényle éventuellement substitué en position -2 par un radical alcoyle ou alcoyloxy (1 ou 2 atomes de carbone), et le symbole R'4 représente un atome de fluor ou un radical hydroxy, et le symbole R5 représente un atome d'hydrogène ou bien les symboles R'4 et R5 représentent des radicaux hydroxy, ou bien le symbole R'4 forme avec R5 une liaison.the symbol R'3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical (1 or 2 carbon atoms), and the symbol R ' 4 represents a fluorine atom or a hydroxy radical, and the symbol R5 represents a hydrogen atom or the symbols R'4 and R5 represent hydroxy radicals, or the symbol R'4 forms with R5 a bond.
le symbole R"3 représente un atome d'hydrogène et le symbole R"4 représente un atome de fluor ou un radical hydroxy, ou bien le symbole R"3 représente un radical phényle éventuellement substitué en position -2 par un radical alcoyle ou alcoyloxy (1 ou 2 atomes de carbone) , et le symbole R"4 est un radical hydroxy, ou bien les symboles R"3 et R" forment ensemble un radical oxo.the symbol R "3 represents a hydrogen atom and the symbol R" 4 represents a fluorine atom or a hydroxy radical, or else the symbol R "3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical (1 or 2 carbon atoms), and the symbol R "4 is a hydroxy radical, or else the symbols R" 3 and R "together form an oxo radical.
le symbole n est un nombre entier de 0 à 2;the symbol n is an integer from 0 to 2;
étant entendu que les produits de formule générale (lia), (Ilb) et (Ile) peuvent présenter des formes stéréoisomères qui sont décrites plus en détail dans les demandes de brevet européen EP 429 366, EP 514 273 et EP 514 275; que les produits de formule générale (Ild) se présentent sous la forme (3aS,4S,7aS) ou (3aRS, 4RS, 7aRS) ou les mélanges de ces formes, si R4 est hydroxy ou fluor et R5 est hydrogène, ou se présentent sous la forme (3aS, 4S, 5S, 7aS) ou (3aRS, 4RS, 5RS, 7aRS) ou les mélanges de ces formes, si R4 et R sont hydroxy, ou se présentent sous la forme (3aS,7aR) ou (3aRS,7aSR) ou les mélanges de ces formes, si R4 forme avec R5 une liaison; et que les produits de formule générale (Ile) se présentent sous la forme (3aS,7R,7aR) , (3aR,7S,7aS) ou (3aRS, 7SR, 7aSR) , si R4 est hydroxy et R3 est un radical phényle, ou se présentent sous la forme (3aR,7S,7aS) , (3aS,7R,7aR) ou (3aRS, 7SR, 7aSR) ou leurs mélanges, si R3 est hydrogène et R4 est hydroxy, ou se présentent sous la forme (3aR,7R,7aS) , (3aS,7S,7aR) ou (3aRS, 7RS, 7aSR) ou leurs mélanges, si R3 est hydrogène et R est fluor, ou se présentent sous la forme (3aS,7aR), (3aR,7aS) ou (3aRS,7aSR) ou leurs mélanges, si R3 forme avec R4 un radical oxo.it being understood that the products of general formula (IIa), (Ilb) and (Ile) can have stereoisomeric forms which are described in more detail in European patent applications EP 429 366, EP 514 273 and EP 514 275; that the products of general formula (Ild) are in the form (3aS, 4S, 7aS) or (3aRS, 4RS, 7aRS) or mixtures of these forms, if R4 is hydroxy or fluorine and R5 is hydrogen, or are present in the form (3aS, 4S, 5S, 7aS) or (3aRS, 4RS, 5RS, 7aRS) or mixtures of these forms, if R4 and R are hydroxy, or are in the form (3aS, 7aR) or (3aRS , 7aSR) or mixtures of these forms, if R4 forms a bond with R5; and that the products of general formula (Ile) are in the form (3aS, 7R, 7aR), (3aR, 7S, 7aS) or (3aRS, 7SR, 7aSR), if R 4 is hydroxy and R3 is a phenyl radical , or are in the form (3aR, 7S, 7aS), (3aS, 7R, 7aR) or (3aRS, 7SR, 7aSR) or their mixtures, if R3 is hydrogen and R4 is hydroxy, or are in the form ( 3aR, 7R, 7aS), (3aS, 7S, 7aR) or (3aRS, 7RS, 7aSR) or their mixtures, if R3 is hydrogen and R is fluorine, or are in the form (3aS, 7aR), (3aR, 7aS) or (3aRS, 7aSR) or their mixtures, if R3 forms with R4 an oxo radical.
Dans la formule (Ilf)In the formula (Ilf)
le symbole R3 représente un radical phényle éventuellement substitué en position -2 par un radical alcoyle ou alcoyloxy contenant 1 ou 2 atomes de carbone ou par un atome de fluor, ou disubst tué par des radicaux trifluoromethyle et les symboles R et R'5 sont identiques ou différents et représentent l'un un atome d'hydrogène ou un radical hydroxy ou alcoyle et l'autre un atome d'hydrogène ou un radical alcoyle, etthe symbol R3 represents a phenyl radical optionally substituted in position -2 by an alkyl or alkyloxy radical containing 1 or 2 carbon atoms or by a fluorine atom, or disubst killed by trifluoromethyl radicals and the symbols R and R'5 are identical or different and one represents a hydrogen atom or a hydroxy or alkyl radical and the other a hydrogen atom or an alkyl radical, and
le symbole R4 représente un radical hydroxy, ou bien le symbole R4 représente un atome de fluor si les symboles R5 et R'5 représentent un atome d'hydrogène ou un radical alcoyle, ou bien le symbole R4 forme avec R une liaison et,the symbol R4 represents a hydroxy radical, or else the symbol R4 represents a fluorine atom if the symbols R5 and R'5 represent a hydrogen atom or an alkyl radical, or else the symbol R4 forms with R a bond and,
le symbole Rg représente un atome d'hydrogène ou un radical alcoyle, hydroxy ou hydroxyalcoyle, etthe symbol Rg represents a hydrogen atom or an alkyl, hydroxy or hydroxyalkyl radical, and
les symboles R représentent l'un un atome d'hydrogène, un radical alcoyle, un radical hydroxy ou hydroxyalcoyle et l'autre un atome d'hydrogène, un radical alcoyle, phényle ou hydroxyalcoyle,the symbols R represent one a hydrogen atom, an alkyl radical, a hydroxy or hydroxyalkyl radical and the other a hydrogen atom, an alkyl, phenyl or hydroxyalkyl radical,
les radicaux alcoyle et acyle cités sont droits ou ramifiés et contiennent 1 à 4C (sauf mention spéciale) , sous forme racémique, sous les formes stéréoisomères de structure :the alkyl and acyl radicals mentioned are straight or branched and contain 1 to 4C (unless special mention), in racemic form, in stereoisomeric forms of structure:
Figure imgf000011_0001
Figure imgf000011_0001
sous ses formes (R) ou (S) sur la chaîne -CHR-]R2, ou sous forme du mélange de plusieurs de ces formes.in its forms (R) or (S) on the chain -CHR- ] R2, or in the form of a mixture of several of these forms.
A titre d'exemple, parmi les produits de la classe des 3-ammo-quιnu- clιdιnes-2-substιtuées, de la classe des pipéridines 2 , 3-dιsubstι- tuées , de la classe des 3-ammo-pιpérιdmes-2-substιtuées , on peut citer ceux de formule générale :By way of example, among the products of the class of 3-ammo-quιnu- clιdιnes-2-substituted, of the class of piperidines 2, 3-desubstituted, of the class of 3-ammo-pιpérιdmes-2- substituted, we can cite those of general formula:
Figure imgf000011_0002
Figure imgf000011_0002
sous leurs formes stéréoisomères ou leurs mélanges, dans laquelle A) le cyclein their stereoisomeric forms or mixtures thereof, in which A) the cycle
Figure imgf000012_0001
Figure imgf000012_0001
représente une 3-ammo-quιnuclιdιne-2-substιtuée de structurerepresents a 3-ammo-quιnuclιdιne-2-substituted structure
Figure imgf000012_0002
Figure imgf000012_0002
dans laquellein which
R-l est -NH-CH2-R, =N-CH2-R ou -N=CH-R, pour lequelRl is -NH-CH 2 -R, = N-CH 2 -R or -N = CH-R, for which
R est cycloalcoyle (5-7C) , norbornyle, pyrrolyle, thienyle, pyridyle, dolyle, biphényle, 2 , 3-dιhydrobenzofuranyle, alcoyloxythiényle dont la partie alcoyle contient 1 à 3 atomes de carbone, hydroxypyridyle, quinolyle, naphtyle, alcoylox /naphtyle dont la partie alcoyle contient 1 à 3 atomes de carbone, 2, 3-méthylènedιoxyphényle ou phényle pouvant être substitué par 1 ou 2 substituants choisis parmi cyano, nitro, amino, N-monoalcoylammo, fluor, chlore, brome, trifluoromethyle, alcoyle , alcoyloxy , allyloxy, hydroxy, carboxy, alcoyloxycarbonyle, benzyloxycarbonyle, carboxybenzyloxy , alcoyloxy- carbonylbenzyloxy , carboxamido ou N,N-dιalcoylcarboxamιdo,R is cycloalkyl (5-7C), norbornyle, pyrrolyle, thienyle, pyridyle, dolyle, biphenyle, 2, 3-dιhydrobenzofuranyl, alcoyloxythienyl of which the alkyl part contains 1 to 3 carbon atoms, hydroxypyridyle, quinolyle, naphthyle / alaphyl / the alkyl part contains 1 to 3 carbon atoms, 2, 3-methylenedιoxyphenyl or phenyl which may be substituted by 1 or 2 substituents chosen from cyano, nitro, amino, N-monoalkylammo, fluorine, chlorine, bromine, trifluoromethyl, alkyl, alkyloxy, allyloxy, hydroxy, carboxy, alkyloxycarbonyl, benzyloxycarbonyl, carboxybenzyloxy, alkyloxycarbonylbenzyloxy, carboxamido or N, N-dιalcoylcarboxamιdo,
R2 est un radical Ar-CHR'- pour lequelR 2 is an Ar-CHR'- radical for which
R' est alcoyle ramifié (3-4C) , alcenyle ramifié (5-6C) , cycloalcoyle (5-7C), furyle, thienyle, pyridyle, mdolyle, biphényle ou phényle pouvant être substitué par 1 ou 2 substituants choisis parmi fluor, chlore, brome, trifluoromethyle, alcoyle , alcoyloxy , carboxy, alcoyloxycarbonyle, benzyloxycarbonyle, phénylalcoyle, allyloxy ou hydroxy ,R 'is branched alkyl (3-4C), branched alkenyl (5-6C), cycloalkyl (5-7C), furyl, thienyl, pyridyl, mdolyle, biphenyl or phenyl which can be substituted by 1 or 2 substituents chosen from fluorine, chlorine , bromine, trifluoromethyl, alkyl, alkyloxy, carboxy, alkyloxycarbonyl, benzyloxycarbonyl, phenylalkyl, allyloxy or hydroxy,
Ar est un radical thienyle ou phényle pouvant être substitué par 1 ou 2 substituants choisis parmi fluor, chlore, brome, trifluoromethyle, alcoyle ou alcoyloxy , et R3 est un atome d'hydrogène ou un radical alcoyle (1-4C) situé en position 5,Ar is a thienyl or phenyl radical which can be substituted with 1 or 2 substituents chosen from fluorine, chlorine, bromine, trifluoromethyl, alkyl or alkyloxy, and R3 is a hydrogen atom or an alkyl radical (1-4C) located in position 5,
sauf mention spéciale, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée et contiennent 1 à 3 atomes de carbone.Unless otherwise stated, the radicals and alkyl portions are in a straight or branched chain and contain 1 to 3 carbon atoms.
B) le cycleB) the cycle
Figure imgf000013_0001
Figure imgf000013_0001
représente une pipéridine 2 , 3-disubstituée de structurerepresents a 2, 3-disubstituted piperidine
Figure imgf000013_0002
Figure imgf000013_0002
dans laquellein which
R-| est -X-CH2-R pour lequel X est un atome d'oxygène ou de soufre, et R est phényle éventuellement substitué par 1 à 3 radicaux identiques ou différents choisis parmi alcoyle, alcenyle (2-6C) , alcynyle (2- 6C) , halogène, cyano, nitro, trifluoromethyle, triméthylsilyle, -OR' , -SR', -SOR', -S02R', -NR'R", -NR'COR", -NR'C02R", -C02R' ou -CONR'R" pour lesquels R' et R" identiques ou différents représentent hydrogène, alcoyle, phényle ou trifluoromethyle,R- | is -X-CH 2 -R for which X is an oxygen or sulfur atom, and R is phenyl optionally substituted by 1 to 3 identical or different radicals chosen from alkyl, (2-6C) alkenyl, (2- 6C), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR ', -SR', -SOR ', -S0 2 R', -NR'R ", -NR'COR", -NR'C0 2 R " , -C0 2 R 'or -CONR'R "for which R' and R" identical or different represent hydrogen, alkyl, phenyl or trifluoromethyl,
R est phényle, naphtyle, indazolyle, thienyle, furyle, pyridyle, thiazolyle, tétrazolyle, quinolyle, benzhydryle ou benzyle tous ces radicaux pouvant être également substitués par alcoyle, alcoyloxy, halogène ou trifluoromethyle,R is phenyl, naphthyl, indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl, quinolyl, benzhydryl or benzyl all these radicals which may also be substituted by alkyl, alkyloxy, halogen or trifluoromethyl,
Y est -(CH2)n- pour lequel n égale 1 à 3, chaque carbone de cette chaîne pouvant être substitué par R3 et/ou R R3 et R5 sont indépendamment H, halogène, -CH2OR° , alcoyle, oxo, COOR°° ou CONR^R000 pour lesquels R° est H, alcoyle ou phényle, R°° est hydrogène ou alcoyle et R000 est hydrogène ou alcoyle,Y is - (CH 2 ) n - for which n equals 1 to 3, each carbon in this chain being able to be substituted by R3 and / or R R 3 and R 5 are independently H, halogen, -CH 2 OR °, alkyl, oxo, COOR °° or CONR ^ R 000 for which R ° is H, alkyl or phenyl, R °° is hydrogen or alkyl and R 000 is hydrogen or alkyl,
R4 est H, COR°, COOR00, COCONRR000, COCOOR00 ou alcoyle éventuellement substitué par [COORc C0NRo OoOR- OOO OH, CN, COR°, -NR00R000, C(N0H)NRooR000, CONHphénylalcoyle (alcoyle 1 -4C) , COCOOR00,R 4 is H, COR °, COOR 00 , COCONR R 000 , COCOOR 00 or alkyl optionally substituted by [COOR c C0NR o O o OR- OOO OH, CN, COR °, -NR 00 R 000 , C (N0H) NR oo R 000 , CONHphenylalkyl (alkyl 1 -4C), COCOOR 00 ,
C0C0NRooRoo° ou phényle éventuellement substitué (par 1 ou plusieurs substituants alcoyle, alcoyloxy, halogène ou CF3] , R° R°° et R°°° sont dé inis comme précédemment ,C0C0NR oo R oo ° or phenyl optionally substituted (by 1 or more alkyl, alkyloxy, halogen or CF3 substituents], R ° R °° and R °°° are defined as above,
étant entendu que sauf mention spéciale, les radicaux et parties alcoyle cités ci-dessus sont en chaîne droite ou ramifiée ou cyclique et contiennent de 1 à 6 atomes de carbone;it being understood that, unless otherwise indicated, the radicals and alkyl parts mentioned above are in straight or branched or cyclic chain and contain from 1 to 6 carbon atoms;
c) le cycle :c) the cycle:
Figure imgf000014_0001
Figure imgf000014_0001
est un cycle de formuleis a cycle of formula
Figure imgf000014_0002
Figure imgf000014_0002
R11-(CH2)m-Rl0 R 11 - (CH 2 ) mR l0
dans laquellein which
X est (CH2)n dans lequel n est un entier de 1 à 6 et dans lequel chacune des liaisons simples C-C peuvent être remplacées par une double liaison et dans lequel chaque carbone peut être éventuellement substitué par R8,X is (CH 2 ) n in which n is an integer from 1 to 6 and in which each of the CC single bonds can be replaced by a double bond and in which each carbon can be optionally substituted by R 8 ,
R6 est hydrogène, alcoyle en chaîne droite ou ramifiée, cycloalcoyle (3-7C) dans lequel un des carbones peut être remplacé par un atome d'azote, de soufre ou d'oxygène, R6 peut également être un aryle choisi parmi biphényle, phényle, phénylalcoyle, benzhydryle, benzyle, indanyle et naphtyle ou un hétéroaryle choisi parmi thienyle, furyle, pyridyle, thiazolyle, isothiazolyle, oxazolyle, isoxazolyle, triazo- lyle, tétrazolyle, quinolyle, ces aryles et hétéroaryles étant éventuellement substitués par un ou plusieurs halogène, nitro, alcoyle (1-1 OC), mono ou di ou trifluoro-alcoyle (1-1 OC), alcoyloxy (1-1 OC), mono ou di ou trifluoro-alcoyloxy (1-1 OC), amino, hydroxyalcoyle, alcoyloxyalcoyle, alcoylamino, alcoyloxycarbonyle, alcoyloxycarbony- lalcoyle, alcoylcarbonyloxy, alcoylcarbonylalcoyloxy, alcoylcarbo- nyle, alcoylcarbonylalcoyle, dialcoylamino, CO-NH-alcoyle, alcoyl-CO- NH-alcoyle, NHCHO et NH-CO-alcoyle, dans lesquels les phényles des benzhydryles peuvent être éventuellement remplacés par naphtyle, thienyle, furyle ou pyridyle,R 6 is hydrogen, straight or branched chain alkyl, cycloalkyl (3-7C) in which one of the carbons can be replaced by an atom nitrogen, sulfur or oxygen, R 6 may also be an aryl chosen from biphenyl, phenyl, phenylalkyl, benzhydryl, benzyl, indanyl and naphthyl or a heteroaryl chosen from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, quinolyl, these aryls and heteroaryls being optionally substituted by one or more halogen, nitro, alkyl (1-1 OC), mono or di or trifluoroalkyl (1-1 OC), alkyloxy (1 -1 OC), mono or di or trifluoroalkyloxy (1-1 OC), amino, hydroxyalkyl, alkyloxyalkyl, alkyllamino, alkyloxycarbonyl, alkylcarbonylalkyl, alkyoycarbonyl, alkylcarbonylalkyl, alkylcarbonyl, alkylcarbonyl , alkyl-CO-NH-alkyl, NHCHO and NH-CO-alkyl, in which the phenyls of the benzhydryls can be optionally replaced by naphthyl, thienyl, furyl or pyridyl,
R7 représente hydrogène, phényle ou alcoyle,R 7 represents hydrogen, phenyl or alkyl,
ou bien R6 et R7 forment ensemble avec l'atome de carbone auquel ils sont rattachés un carbocyclique saturé ayant 3 à 7 atomes de carbone et dans lequel un des atomes de carbone peut être éventuellement remplacé par oxygène, soufre ou azote,or else R 6 and R 7 form together with the carbon atom to which they are attached a saturated carbocyclic having 3 to 7 carbon atoms and in which one of the carbon atoms can be optionally replaced by oxygen, sulfur or nitrogen,
Ra et R9 représentent indépendamment hydrogène, hydroxy, halogène, amino, oxo, nitrile, hydroxyalcoyle, alcoyloxyalcoyle, alcoylamino, dialcoylamino, halogénoalcoyle, alcoyloxy, alcoyloxycarbonyle, alcoy- loxycarbonylalcoyle, alcoylcarbonyloxy, alcoylcarbonylalcoyloxy, al- coylcarbonyle, alcoylcarbonylalcoyle, et les radicaux mentionnés pour R6,R a and R 9 independently represent hydrogen, hydroxy, halogen, amino, oxo, nitrile, hydroxyalkyl, alkyloxyalkyl, dialkoylamino, haloalkyl, alkyloxy, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonylalkylcarbonyloxyalkyl mentioned for R 6 ,
Rio est NHCOR12, NHCH2R12, NHSO2R12 ou un des radicaux mentionnés pour R6, R8 et R9,Rio is NHCOR12, NHCH2R12, NHSO 2 R 12 or one of the radicals mentioned for R 6 , R 8 and R 9 ,
R11 est oxi ino ou un des radicaux mentionnés pour R6, Re et R9,R11 is oxi ino or one of the radicals mentioned for R 6 , R e and R 9 ,
Ri2 est alcoyle, hydrogène, phénylalcoyle ou phényle éventuellement substitué par alcoyle, m est un entier de 0 à 8, dans lequel chacune des liaisons simples C-C peuvent être remplacées par une double liaison ou une triple liaison et les carbones sont éventuellement substitués par R ,Ri2 is alkyl, hydrogen, phenylalkyl or phenyl optionally substituted by alkyl, m is an integer from 0 to 8, in which each of the CC single bonds can be replaced by a double bond or a triple bond and the carbons are optionally substituted by R,
et soit R-| est un radical -NH-CH2-R pour lequel R représente un radi- cal phényle trisubstitue par des radicaux X-\ à X3 pour lesquels X-| est H, alcoyle (1-1 OC) éventuellement substitué par 1 à 3 atomes de fluor ou alcoyloxy (1-1 OC) éventuellement substitué par 1 à 3 atomes de fluor et, X2 et X3 sont indépendamment H, halogène N02, alcoyle (1-1 OC) éventuellement substitués par 1 à 3 atomes de fluor, alcoy- loxy (1-1 OC) éventuellement substitués par 1 à 3 atomes de fluor, OH, CF3, CN, phényle, NH2 , alcoylamino, dialcoylamino, alcoylcarbamoyle, alcoylcarba oylalcoyle, hydroxyalcoyle, NHCHO, NHCOalcoyle (alcoyle 1-6C) ou alcoyloxyalcoyle (dont les parties alcoyle contiennent 1- 4C) ,and let R- | is a radical -NH-CH 2 -R for which R represents a phenyl radical trisubstituted by radicals X- \ to X3 for which X- | is H, alkyl (1-1 OC) optionally substituted with 1 to 3 fluorine atoms or alkyloxy (1-1 OC) optionally substituted with 1 to 3 fluorine atoms and, X 2 and X3 are independently H, halogen NO 2 , alkyl (1-1 OC) optionally substituted with 1 to 3 fluorine atoms, alkyloxy (1-1 OC) optionally substituted with 1 to 3 fluorine atoms, OH, CF 3 , CN, phenyl, NH 2 , alkylamino, dialcoylamino, alkylcarbamoyl, alkylcarba oylalkoyl, hydroxyalkyl, NHCHO, NHCOalkyl (1-6C alkyl) or alkyloxyalkyl (in which the alkyl parts contain 1- 4C),
soit R, représente -N(R°) CH2-R00, R° est hydrogène ou alcoyle (1-8C) éventuellement substitué par hydroxy, alcoyloxy ou fluor et R00 est cycloalcoyle (3-7C) dans lequel un des carbones peut être remplacé par un atome d'azote, de soufre ou d'oxygène et éventuellement substitué par 1 ou 2 substituants, un aryle choisi parmi phényle, naph- tyle, mdanyle ou un hétéroaryle choisi parmi thienyle, furyle, pyridyle, thiazolyle, îsothiazolyle, oxazolyle, isoxazolyle, triazolyle, tétrazolyle et quinolyle, les aryles et hétéroaryles étant éventuellement substitués par un ou plusieurs substituants, les substituants du cycloalcoyle, des aryles et hétéroaryle étant choisis parmi halo- gène, nitro, alcoyle, alcoyloxy, trifluoromethyle, amino, alcoylamino, phényle, CO-NH-alcoyle, alcoyl-CO-NH-alcoyle, NHCHO et NH-CO- alcoyle,either R represents -N (R °) CH 2 -R 00 , R ° is hydrogen or alkyl (1-8C) optionally substituted with hydroxy, alkyloxy or fluorine and R 00 is cycloalkyl (3-7C) in which one of the carbons may be replaced by a nitrogen, sulfur or oxygen atom and optionally substituted by 1 or 2 substituents, an aryl chosen from phenyl, naphthyl, mdanyl or a heteroaryl chosen from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl , oxazolyle, isoxazolyle, triazolyle, tétrazolyle and quinolyle, the aryls and heteroaryl being optionally substituted by one or more substituents, the substituents of the cycloalkyl, aryls and heteroaryl being chosen among halogen, nitro, alkyl, alkyloxy, trifluoromethyle, alkylamino, phenyl, CO-NH-alkyl, alkyl-CO-NH-alkyl, NHCHO and NH-CO-alkyl,
étant entendu que (a) si m est zéro, R est absent, (b) ni R8, R9, R10 et Rπ ne peuvent former avec l'atome de carbone auquel l est ratta- ché un cycle avec R7, (c) si R8 et R9 sont rattachés au même atome de carbone, ces derniers sont indépendamment hydrogène, fluoro, alcoyle, hydroxyalcoyle et alcoyloxyalcoyle, ou forment ensemble avec l'atome de carbone auquel ils sont rattachés un carbocycle saturé qui forme un spiro avec le cycle azoté auquel ls sont rattachés, (d) si n est égal à 2 et l'un des R8 ou R9 est 5-hydroxyalcoyle ou 5-alcoyoxy-al- coyle, l'autre est hydrogène ou alcoyle (1-3C), (e) si n est égal à 2, ni R8 ni R9 ne représentent 4-hydroxyalcoyle ou 4-alcoyloxyalcoyle, (f) si, aucun des i , X2 et X3 n'est un alcoyloxy fluoré, au moins un des Rj , R6, R7 est un aryle substitué par un alcoyloxy fluoré,it being understood that (a) if m is zero, R is absent, (b) nor R 8 , R 9 , R 10 and Rπ cannot form with the carbon atom to which l is attached a cycle with R 7 , (c) if R 8 and R 9 are attached to the same carbon atom, the latter are independently hydrogen, fluoro, alkyl, hydroxyalkyl and alkyloxyalkyl, or together form with the carbon atom to which they are attached a saturated carbocycle which forms a spiro with the nitrogen cycle to which ls are attached, (d) if n is equal to 2 and one of R 8 or R 9 is 5-hydroxyalkyl or 5-alkyloxyalkyl, the other is hydrogen or (1-3C) alkyl, (e) if n is equal to 2, nor R8 and R9 do not represent 4-hydroxyalkyl or 4-alkyloxyalkyl, (f) if none of i, X 2 and X 3 is a fluorinated alkyloxy, at least one of Rj, R 6 , R 7 is an aryl substituted by a fluorinated alkyloxy,
étant entendu que sauf mention spéciale, les radicaux et parties alcoyle cités ci-dessus sont en chaîne droite ou ramifiée ou cyclique et contiennent de 1 à 6 atomes de carbone) ;it being understood that, unless otherwise stated, the radicals and alkyl parts mentioned above are in a straight or branched or cyclic chain and contain from 1 to 6 carbon atoms);
d) le cycled) the cycle
Figure imgf000017_0001
Figure imgf000017_0001
représente une 3-amιno-pιpérιdme-2-substιtuée ou un dérivé trisubstitue <~X la morpholme de structure :represents a 3-amιno-pιpérιdme-2-substιturée or a trisubstituted derivative < ~ X the structure morpholme:
Figure imgf000017_0002
Figure imgf000017_0002
R,R,
dans laquellein which
R-| est -NH-CH2-R pour lequel R est aryle choisi parmi mdanyle, phényle et naphtyle; hétéroaryle choisi parmi thienyle, furyle, pyridyle et quinolyle; cycloalcoyle (3-7C) dans lequel l'un des atomes de carbone peut être remplacé par N, 0 ou S et où les groupes aryle et hé- teroaryle peuvent éventuellement être substitués par 1 ou plusieurs substituants et le radical cycloalcoyle peut être éventuellement substitué par 1 ou 2 substituants, ces substituants étant choisis indépendamment parmi chlore, fluor, brome, iode, nitro, amino, al- coylthio (1 à 10C), alcoylsulfmyle (1-10C), alcoylsulfonyle (1-10C), phényle, phénoxy, alcoyld à 10C) suifonylammo, alcoyl(1- 1 OC) sulfonylam oalcoyle (1 -1 OC) , dialcoyl (1 -1 OC) aminoalcoyle (1-1 OC) , cyano, hydroxy, cycloalcoyloxy (3-7C) , alcoyl (1 -6C) amino, dialcoyl (1 - 6C)amιno, H-CO-NH-, alcoyl (1 -6C) -CO-NH- , alcoyle (1-10C) éventuellement substitué par 1 à 3 fluor ou alcoyloxy (1-1 OC) éventuellement substitué par 1 à 3 fluor etR- | is -NH-CH 2 -R for which R is aryl chosen from mdanyl, phenyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl and quinolyl; cycloalkyl (3-7C) in which one of the carbon atoms can be replaced by N, 0 or S and where the aryl and heteroaryl groups can optionally be substituted by 1 or more substituents and the cycloalkyl radical can be optionally substituted with 1 or 2 substituents, these substituents being independently chosen from chlorine, fluorine, bromine, iodine, nitro, amino, alkylthio (1 to 10C), alkylsulfmyl (1-10C), alkylsulfonyl (1-10C), phenyl, phenoxy , 10C alkyl) suifonylammo, alkyl (1- 1 OC) sulfonylam oalkyl (1 -1 OC), dialcoyl (1 -1 OC) aminoalkyl (1-1 OC), cyano, hydroxy, cycloalkyloxy (3-7C), alkyl (1 -6C) amino, dialcoyl (1 - 6C) amιno, H-CO-NH-, alkyl (1 -6C) -CO-NH-, alkyl (1-10C) optionally substituted with 1 to 3 fluorine or alkyloxy (1-1 OC) optionally substituted with 1 to 3 fluorine and
R2 représente thienyle, benzhydryle, naphtyle ou phényle éventuellement substitué par 1 à 3 substituants choisis parmi chlore, fluor, brome, iode, cycloalcoyloxy (3-7C) , alcoyle (1-10C) éventuellement substitués par 1 à 3 atomes de fluor ou alcoyloxy (1-1 OC) éventuelle- ment substitués par 1 à 3 atomes de fluor;R 2 represents thienyl, benzhydryl, naphthyl or phenyl optionally substituted with 1 to 3 substituents chosen from chlorine, fluorine, bromine, iodine, cycloalkyloxy (3-7C), alkyl (1-10C) optionally substituted with 1 to 3 fluorine atoms or alkyloxy (1-1 OC) optionally substituted with 1 to 3 fluorine atoms;
et soit X est un groupement -CH2-, R3 est un atome d'hydrogène,and either X is a group -CH 2 -, R3 is a hydrogen atom,
soit X est un atome d'oxygène, R-| est 3,5- bis (trifluorométhyl) benzyloxy, R2 est phényle et R3 est (5-oxo-1H, 4H- 1,2, 4-trιazolo) méthyle .let X be an oxygen atom, R- | is 3,5- bis (trifluoromethyl) benzyloxy, R 2 is phenyl and R3 is (5-oxo-1H, 4H-1,2, 4-trιazolo) methyl.
A titre d'exemple, parmi les produits de la classe des dérivés aromatiques substitués on peut citer ceux de formule :By way of example, among the products of the class of substituted aromatic derivatives, mention may be made of those of formula:
Figure imgf000018_0001
R^2
Figure imgf000018_0001
R ^ 2
dans laquellein which
1) soit R est Q-CH2- pour lequel Q est phényle, naphtyle, mdolyle, benzothiophényle, benzofuranyle, benzyle ou dazolyle, ces différents cycles étant éventuellement substitués par un ou plusieurs alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, nitro, trifluoromethyle, trifluorosilyle, ORa', SRa', SORa', S02Ra', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb' et l'mdolyle pouvant être éventuellement substitué sur l'azote par alcoyle, phénylalcoyle, COORa ' ou CONRa 'Rb ' ,1) or R is Q-CH 2 - for which Q is phenyl, naphthyl, mdolyl, benzothiophenyl, benzofuranyl, benzyl or dazolyl, these different rings being optionally substituted by one or more alkyl, alkenyl (2-6C), alkynyl (2 -6C), halogen, cyano, nitro, trifluoromethyl, trifluorosilyl, ORa ', SRa', SORa ', S0 2 Ra', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb ' and the mdolyl which may be optionally substituted on nitrogen by alkyl, phenylalkyl, COORa 'or CONRa' Rb ',
Z est 0, S ou NR" pour lequel R" est H ou alcoyle, X et Y sont H ou forment ensemble =0,Z is 0, S or NR "for which R" is H or alkyl, X and Y are H or together form = 0,
R-| et R2 sont indépendamment H, alcoyle pouvant être substitué (par OH, CN, CORa, COORa, CONRaRb, ou NRaRb) , CORa, COORa, CONRaRb, CONRaCOORb, S02Ra ou phénylalcoyle (1 -4C) éventuellement substitué sur le phényle par un ou plusieurs alcoyle, alcoyloxy, halogène ou trifluoromethyle ,R- | and R 2 are independently H, alkyl which can be substituted (by OH, CN, CORa, COORa, CONRaRb, or NRaRb), CORa, COORa, CONRaRb, CONRaCOORb, SO 2 Ra or phenylalkyl (1 -4C) optionally substituted on phenyl by one or more alkyl, alkyloxy, halogen or trifluoromethyl,
Ra et Rb sont indépendammentH, alcoyle ( 1 -12C) , trifluoromethyle ou phényle éventuellement substitué par un ou plusieurs alcoyle, alcoyloxy, halogène ou trifluoromethyle,Ra and Rb are independently H, (1-12C) alkyl, trifluoromethyl or phenyl optionally substituted by one or more alkyl, alkyloxy, halogen or trifluoromethyl,
R est H ou alcoyle,R is H or alkyl,
R' est CH(R4)R5,R 'is CH (R 4 ) R 5 ,
R4 est hydrogène, alcoyle ou phényle éventuellement substitué par 1 à 3 alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, N02, CF3, triméthylsilyle, ORa', SRa', SORa', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb'R 4 is hydrogen, alkyl or phenyl optionally substituted by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, cyano, N0 2 , CF3, trimethylsilyl, ORa ', SRa', SORa ', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb '
R5 est phényle éventuellement substitué par 1 à 3 alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, N02, CF3, triméthylsilyle, ORa', SRa', SORa', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb' ,R 5 is phenyl optionally substituted with 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, cyano, NO 2 , CF3, trimethylsilyl, ORa ', SRa', SORa ', NRa'Rb' , NRa'CORb ', NRa'COORb', COORa 'or CONRa'Rb',
Ra' et Rb' sont indépendamment H, alcoyle, trifluoromethyle ou phényleRa 'and Rb' are independently H, alkyl, trifluoromethyl or phenyl
sauf mention contraire, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée ou cyclique et contiennent 1 à 6C.unless otherwise stated, the radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C.
2) soit R est Q-CH - pour lequel Q est phényle substitué par un ou plusieurs halogènes, naphtyle, indolyle, benzothiophényle, benzofuranyle, benzyle ou 9-fluorényle, ces cycles étant éventuellement substitués par alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, nitro, trifluoromethyle, triméthylsilyle, ORa', SRa', SORa', S02Ra', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb' et l'indolyle pouvant être éventuellement substitué sur l'azote par alcoyle, phénylalcoyle éventuellement substitué, COORa' ou CONRa'Rb',2) either R is Q-CH - for which Q is phenyl substituted by one or more halogens, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, (2-6C) alkenyl, alkynyl (2-6C), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa ', SRa', SORa ', S0 2 Ra', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa 'Rb' and indolyl which may be optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa 'or CONRa'Rb',
R-| et R2 sont indépendamment H, alcoyle pouvant être substitué (par OH, CN, CORa, COORa, CONRaRb, ou NRaRb) , CORa, COORa, CONRaRb, CONRaCOORb, COalcoylNRaRb, S0Ra ou phénylalcoyle (1 -4C) éventuellement substitué sur le phényle par un ou plusieurs alcoyle, alcoyloxy, halogène ou trifluoromethyle,R- | and R 2 are independently H, alkyl which can be substituted (by OH, CN, CORa, COORa, CONRaRb, or NRaRb), CORa, COORa, CONRaRb, CONRaCOORb, COalcoylNRaRb, S0Ra or phenylalkyl (1 -4C) optionally substituted on phenyl by one or more alkyl, alkyloxy, halogen or trifluoromethyl,
Ra et Rb sont indépendamment H, alcoyle (1 -12C) , phényle éventuellement substitué par alcoyle, alcoyloxy, halogène ou trifluoromethyle ou phénylalcoyle (1 -4C) éventuellement substitué sur le phényle par alcoyle, alcoyloxy, halogène ou trifluoromethyleRa and Rb are independently H, alkyl (1 -12C), phenyl optionally substituted by alkyl, alkyloxy, halogen or trifluoromethyl or phenylalkyl (1 -4C) optionally substituted on phenyl by alkyl, alkyloxy, halogen or trifluoromethyl
l'un des X et Y est hydrogène et l'autre est hydroxy ou alcoyloxy; ou bien X et Y forment ensemble =0, =N0H ou =N0alcoyle,one of X and Y is hydrogen and the other is hydroxy or alkyloxy; or else X and Y together form = 0, = N0H or = N0alkyl,
R3 est hydrogène, alcoyle, alcenyle (2-6C) ,R 3 is hydrogen, alkyl, alkenyl (2-6C),
-Z-R' représente X^ R' dans laquelle est une éventuelle liaison covalente,-Z-R 'represents X ^ R' in which is a possible covalent bond,
R' est phényle éventuellement substitué par 1 à 3 alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, N02 , CF3 , triméthylsilyle, ORa', SRa', SORa', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb'R 'is phenyl optionally substituted by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, cyano, NO 2 , CF3, trimethylsilyl, ORa', SRa ', SORa', NRa'Rb ' , NRa'CORb ', NRa'COORb', COORa 'or CONRa'Rb'
Ra' et Rb' sont indépendamment H, alcoyle, trifluoromethyle ou phényle,Ra 'and Rb' are independently H, alkyl, trifluoromethyl or phenyl,
sauf mention contraire, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée ou cyclique et contiennent 1 à 6Cunless otherwise stated, the radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C
3) soit R est Q-CH2- pour lequel Q est phényle substitué par un ou plusieurs halogène, naphtyle, indolyle, benzothiophényle, benzofuranyle, benzyle ou 9-fluorènyle, ces cycles étant éventuellement substitués par alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, nitro, trifluoromethyle, triméthylsilyle, ORa', SRa', SORa', S02Ra', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb' et 1' dolyle pouvant être éventuellement substitué sur l'azote par alcoyle, phénylalcoyle éventuellement substitué, COORa' ou CONRa'Rb',3) either R is Q-CH 2 - for which Q is phenyl substituted by one or more halogen, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, alkenyl (2-6C) , (2-6C) alkynyl, halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa ', SRa', SORa ', S0 2 Ra', NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb 'and 1 dolyle which may be optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa 'or CONRa'Rb',
Ri est hydrogène ou alcoyleRi is hydrogen or alkyl
R2 est un groupe -CO-W-Rg pour lequel W est une liaison ou une chaîne hydrocarbonée saturée ou insaturée ayant 1 à 6 atomes de carbone et Rg est un groupe azacyclique aromatique ou non aromatique ou azabicy- clique aromatique ou non aromatique, ces derniers contenant éventuellement un ou plusieurs hétéroatomes supplémentaires choisis parmi N, S, 0, NH ou Nalcoyle et pouvant être éventuellement substitués par alcoyle, alcoyloxy, oxo, SH, =S, halogène, trifluoromethyle, NRaRb, NRaCORb, CONRaRb, COORa et CH20Ra,R 2 is a group -CO-W-Rg for which W is a bond or a saturated or unsaturated hydrocarbon chain having 1 to 6 carbon atoms and Rg is an aromatic or non-aromatic azacyclic group or an aromatic or non-aromatic azabicyclic group, the latter optionally containing one or more additional heteroatoms chosen from N, S, 0, NH or Nalcoyl and which can be optionally substituted by alkyl, alkyloxy, oxo, SH, = S, halogen, trifluoromethyle, NRaRb, NRaCORb, CONRaRb, COORa and CH 2 0Ra,
R3 est hydrogène, alcoyle ou alcenyle (2-6C) ,R3 is hydrogen, alkyl or alkenyl (2-6C),
l'un des X et Y est hydrogène et l'autre est hydroxy ou alcoyloxy; ou bien X et Y forment ensemble =0, =N0H ou =N0alcoyle,one of X and Y is hydrogen and the other is hydroxy or alkyloxy; or else X and Y together form = 0, = N0H or = N0alkyl,
-Z-R' représente -^ R' dans laquelle est une éventuelle liaison covalente,-Z-R 'represents - ^ R' in which is a possible covalent bond,
R' est phényle pouvant être substitué sur le cycle par 1 à 3 groupes alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, CN, N02, CF3, triméthylsilyle, ORa', SRa', SORa', NRa'Rb', NRa'CORb', NRa'COORb', COORa' ou CONRa'Rb',R 'is phenyl which can be substituted on the ring by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, CN, NO 2 , CF3, trimethylsilyl, ORa', SRa ', SORa' groups , NRa'Rb ', NRa'CORb', NRa'COORb ', COORa' or CONRa'Rb ',
Ra' et Rb' sont indépendamment H, alcoyle, trifluoromethyle ou phényle,Ra 'and Rb' are independently H, alkyl, trifluoromethyl or phenyl,
sauf mention contraire, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée ou cyclique et contiennent 1 à 6Cunless otherwise stated, the radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C
4) soit R est Q-CH - pour lequel Q est phényle substitué par un ou plusieurs halogène, naphtyle, mdolyle, benzothiophényle, benzofuranyle, benzyle ou 9-fluorényle, ces cycles étant éventuellement substitués par alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, nitro, trifluoromethyle, triméthylsilyle, ORa, SRa, SORa, S02Ra, NRaRb, NRaCORb, NRaCOORb, COORa ou CONRaRb et l' mdolyle pou- vant être éventuellement substitué sur l'azote par alcoyle, phénylalcoyle éventuellement substitué, COORa ou CONRaRb,4) either R is Q-CH - for which Q is phenyl substituted by one or more halogen, naphthyl, mdolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, (2-6C) alkenyl, alkynyl (2-6C), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa, SRa, SORa, S0 2 Ra, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb and the mdolyle for before being optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa or CONRaRb,
Ri est hydrogène ou alcoyle,Ri is hydrogen or alkyl,
R2 est un groupe -CO-V-W-Rg pour lequel V est 0,S, NH ou Nalcoyle, W est une liaison ou une chaîne hydrocarbonée saturée ou saturee ayant 1 à 6 atomes de carbone et Rg est NR7Rg dans lequel R7 et Rg sont indépendamment H, alcoyle, phényle éventuellement substitué par 1 ou plusieurs alcoyle, alcoyloxy, halo ou trifluoromethyle ou phénylalcoyle éventuellement substitué sur le phényle par 1 ou plusieurs alcoyle, alcoyloxy, halo, trifluoromethyle, ou bien un groupe azacy- clique aromatique ou non aromatique ou azabicyclique aromatique ou non aromatique, ces derniers contenant éventuellement un ou plusieurs heteroatomes supplémentaires choisis parmi N, S, O, NH, Nalcoyle ou N-alcoylphényle et pouvant être éventuellement substitués par al- coyle, alcoyloxy, oxo, SH, =S, halogène, trifluoromethyle, NRaRb, NRaCORb, CONRaRb, COORa et CH20Ra,R 2 is a group -CO-VW-Rg for which V is 0, S, NH or Nalcoyle, W is a bond or a saturated or saturated hydrocarbon chain having 1 to 6 carbon atoms and Rg is NR 7 Rg in which R 7 and Rg are independently H, alkyl, phenyl optionally substituted by 1 or more alkyl, alkyloxy, halo or trifluoromethyl or phenylalkyl optionally substituted on phenyl by 1 or more alkyl, alkyloxy, halo, trifluoromethyl, or an aromatic azacyclic group or non-aromatic or aromatic or non-aromatic azabicyclic, the latter optionally containing one or more additional heteroatoms chosen from N, S, O, NH, Nalkyl or N-alkylphenyl and which may be optionally substituted by alkyl, alkyloxy, oxo, SH, = S, halogen, trifluoromethyl, NRaRb, NRaCORb, CONRaRb, COORa and CH 2 0Ra,
R3 est hydrogène, alcoyle ou alcenyle (2-6C) ,R 3 is hydrogen, alkyl or alkenyl (2-6C),
l'un des X et Y est hydrogène et l'autre est hydroxy ou alcoyloxy; ou bien X et Y forment ensemble =0, =N0H ou =N0alcoyle,one of X and Y is hydrogen and the other is hydroxy or alkyloxy; or else X and Y together form = 0, = N0H or = N0alkyl,
-Z-R' représente -^ R' dans laquelle est une éventuelle liaison covalente,-Z-R 'represents - ^ R' in which is a possible covalent bond,
R' est phényle éventuellement substitué sur le cycle par 1 à 3 groupes alcoyle, alcenyle -2-6C) , alcynyle (2-6C) , halogène, CN, N02 , CF3, triméthylsilyle, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa ou CONRaRb dans lesquels Ra et Rb sont Ra et Rb peuvent être H, alcoyle, phényle ou trifluoromethyle,R 'is phenyl optionally substituted on the ring by 1 to 3 alkyl groups, alkenyl -2-6C), alkynyl (2-6C), halogen, CN, NO 2 , CF 3 , trimethylsilyl, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb in which Ra and Rb are Ra and Rb can be H, alkyl, phenyl or trifluoromethyl,
Ra et Rb sont H, alcoyle, phényle ou trifluoromethyle,Ra and Rb are H, alkyl, phenyl or trifluoromethyl,
sauf mention contraire, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée ou cyclique et contiennent 1 à 6C 5) soit R est Q-CH2- pour lequel Q est phényle substitué par un ou plusieurs halogène, naphtyle, indolyle, benzothiophényle, benzofuranyle, benzyle ou 9-fluorènyle, ces cycles étant éventuellement substitués par alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, nitro, trifluoromethyle, triméthylsilyle, ORa, SRa, SORa, S02Ra, NRaRb, NRaCORb, NRaCOORb, COORa ou CONRaRb et l' indolyle pouvant être éventuellement substitué sur l'azote par alcoyle, phénylalcoyle éventuellement substitué, COORa ou CONRaRb,unless otherwise stated, the radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C 5) either R is Q-CH 2 - for which Q is phenyl substituted by one or more halogen, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, alkenyl (2-6C) , (2-6C) alkynyl, halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa, SRa, SORa, S0 2 Ra, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb and indolyl which can be optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa or CONRaRb,
R-i est hydrogène ou alcoyle,R-i is hydrogen or alkyl,
R2 est un groupe -CO-Z' pour lequel Z' est -alcoyl-COOH, phényle, phénylalcoyle où chaque groupe phényle est substitué par carboxy;R 2 is a group -CO-Z 'for which Z' is -alkyl-COOH, phenyl, phenylalkyl where each phenyl group is substituted by carboxy;
R3 est hydrogène, alcoyle ou alcenyle (2-6C) ,R 3 is hydrogen, alkyl or alkenyl (2-6C),
l'un des X et Y est hydrogène et l'autre est hydroxy ou alcoyloxy; ou bien X et Y forment ensemble =0, =N0H ou =N0alcoyle,one of X and Y is hydrogen and the other is hydroxy or alkyloxy; or else X and Y together form = 0, = N0H or = N0alkyl,
-Z-R' représente ^ R' dans laquelle est une éventuelle liaison covalente,-Z-R 'represents ^ R' in which is a possible covalent bond,
R' est phényle éventuellement substitué sur le cycle par 1 à 3 groupes alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, CN, N02, CF3, triméthylsilyle, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa ou CONRaRb,R 'is phenyl optionally substituted on the ring with 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C), halogen, CN, NO 2 , CF 3 , trimethylsilyl, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb,
Ra et Rb sont indépendamment H, alcoyle, phényle ou trifluoromethyle,Ra and Rb are independently H, alkyl, phenyl or trifluoromethyl,
sauf mention contraire, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée ou cyclique et contiennent 1 à 6Cunless otherwise stated, the radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C
6) soit R est Q-CH2- pour lequel Q est phényle substitué par un ou plusieurs halogène, naphtyle, indolyle, benzothiophényle, benzofuranyle, benzyle ou 9-fluorènyle, ces cycles étant éventuellement substitués par alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, cyano, nitro, trifluoromethyle, triméthylsilyle, ORa, SRa, SORa, S02Ra, NRaRb, NRaCORb, NRaCOORb, COORa ou CONRaRb et l' indolyle pou- vant être éventuellement substitué sur l'azote par alcoyle, phénylalcoyle éventuellement substitué, COORa ou CONRaRb,6) either R is Q-CH 2 - for which Q is phenyl substituted by one or more halogen, naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or 9-fluorenyl, these rings being optionally substituted by alkyl, alkenyl (2-6C) , (2-6C) alkynyl, halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, ORa, SRa, SORa, S0 2 Ra, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb and indolyl for before being optionally substituted on nitrogen by alkyl, optionally substituted phenylalkyl, COORa or CONRaRb,
R-i est hydrogène ou alcoyle,R-i is hydrogen or alkyl,
R2 est un groupe -CO-Z' pour lequel Z' est -alcoyl-COOH, phényle, phénylalcoyle où chaque groupe phényle est substitué par carboxy;R 2 is a group -CO-Z 'for which Z' is -alkyl-COOH, phenyl, phenylalkyl where each phenyl group is substituted by carboxy;
R3 est hydrogène, alcoyle ou alcenyle (2-6C) ,R 3 is hydrogen, alkyl or alkenyl (2-6C),
X et Y forment ensemble un radical oxo et -Z-R' représente un radical -NR4~CH2R' pour lequel R' est phényle éventuellement substitué par 1 à 3 groupes alcoyle, alcenyle (2-6C) , alcynyle (2-6C) , halogène, CN, N02, CF3, triméthylsilyle, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa ou CONRaRb dans lesquels Ra et Rb sont H, alcoyle, phényle ou trifluoromethyle, et R4 est H ou alcoyle etX and Y together form an oxo radical and -ZR 'represents a radical -NR4 ~ CH 2 R' for which R 'is phenyl optionally substituted by 1 to 3 alkyl, alkenyl (2-6C), alkynyl (2-6C) groups , halogen, CN, N0 2 , CF 3 , trimethylsilyl, ORa, SRa, SORa, NRaRb, NRaCORb, NRaCOORb, COORa or CONRaRb in which Ra and Rb are H, alkyl, phenyl or trifluoromethyl, and R4 is H or alkyl and
R2 est un groupe -CO-X2-Y2-R6, X2 est une liaison, O, S, NH ou Nalcoyle, Y2 est une liaison ou alkylidène (1-6C) et R6 est NRcRd ou un groupe azacyclique aromatique ou non aromatique ou a_. ibicyclique, aromatique ou non aromatique, ces derniers contenant éventuellement un ou plusieurs heteroatomes supplémentaires choisis parmi S, O, NH ou Nalcoyle et pouvant être éventuellement substitués par alcoyle, alcoyloxy, oxo, SH, =S, halogène, trifluoromethyle, NRaRb, NRaCORb, CONRaRb, COORa et CH20Ra ,R 2 is a group -CO-X2-Y2-R 6 , X 2 is a bond, O, S, NH or Nalcoyl, Y 2 is a bond or alkylidene (1-6C) and R 6 is NRcRd or an azacyclic group aromatic or non-aromatic or a_. ibicyclic, aromatic or non-aromatic, the latter optionally containing one or more additional heteroatoms chosen from S, O, NH or Nalcoyl and which may be optionally substituted by alkyl, alkyloxy, oxo, SH, = S, halogen, trifluoromethyl, NRaRb, NRaCORb, CONRaRb, COORa and CH 2 0Ra,
Ra et Rb sont indépendamment H, alcoyle, phényle ou trifluoromethyle,Ra and Rb are independently H, alkyl, phenyl or trifluoromethyl,
Rc et Rd sont indépendamment hydrogène, alcoyle, phényle éventuellement substitué par alcoyle, alcoyloxy, halogène ou trifluoromethyle ou phénylalcoyle éventuellement substitué par alcoyle, alcoyloxy, halogène ou trifluoromethyle,Rc and Rd are independently hydrogen, alkyl, phenyl optionally substituted by alkyl, alkyloxy, halogen or trifluoromethyl or phenylalkyl optionally substituted by alkyl, alkyloxy, halogen or trifluoromethyl,
sauf mention contraire, les radicaux et portions alcoyle sont en chaîne droite ou ramifiée ou cyclique et contiennent 1 à 6C.unless otherwise stated, the radicals and alkyl portions are in a straight or branched or cyclic chain and contain 1 to 6C.
A titre d'exemple, parmi les dérivés de la classe des sels quaternaires de pipéridines substituées on peut citer ceux de formule générale :
Figure imgf000025_0001
By way of example, among the derivatives of the class of quaternary salts of substituted piperidines, mention may be made of those of general formula:
Figure imgf000025_0001
1 ) dans laquelle :1) in which:
J représente (a) un groupe Ar-CXX'-CX" dans lequel Ar est cycloal- coyle (3-7C) , pyridyle, thienyle ou phényle éventuellement substitué par un ou plusieurs halogène, hydroxy, alcoyloxy (1-3C), alcoyle (1- 3C) , trifluoromethyle, X esthydrogene, X' est hydrogène ou est réuni à X' ' pour former une liaison carbone-carbone ou bien X et X' forment =0, X'' est hydrogène ou avec X' forme une liaison carbone-carbone, (b) un groupe Ar- (CH2) X-CX1 dans lequel Ar est tel que défini ci-dessus, x est 0 ou 1 , X1 est hydrogène si x est 0 ou représente hydroxy, alcoyloxy (1-4C), acyloxy (1-4C), carboxy, carbalcoxy -1-4C), cyano, NHCOalcoyle (alcoyle 1 -6C) , mercapto, alcoylthio (1-4C), ou bien X1 forme avec l'atome de carbone auquel il est lié et avec l'atome de carbone voisin dans la pipéridine une double liaison, Q est alcoyle ou benzyle,J represents (a) an Ar-CXX'-CX "group in which Ar is cycloalkyl (3-7C), pyridyl, thienyl or phenyl optionally substituted by one or more halogen, hydroxy, (1-3C) alkyl, alkyl (1- 3C), trifluoromethyle, X esthydrogene, X 'is hydrogen or is joined to X''to form a carbon-carbon bond or else X and X' form = 0, X '' is hydrogen or with X 'forms a carbon-carbon bond, (b) an Ar- (CH 2 ) X -CX1 group in which Ar is as defined above, x is 0 or 1, X1 is hydrogen if x is 0 or represents hydroxy, alkyloxy (1 -4C), acyloxy (1-4C), carboxy, carbalcoxy -1-4C), cyano, NHCOalkyl (alkyl 1 -6C), mercapto, alkylthio (1-4C), or X1 forms with the carbon atom to which it is linked and with the neighboring carbon atom in piperidine a double bond, Q is alkyl or benzyl,
A~ est un anion et, en particulier, Cl-, Br-, I~, acétate, méthane- suifonate, p. toluènesulfonate,A ~ is an anion and, in particular, Cl-, Br-, I ~ , acetate, methane-sulfonate, p. toluenesulfonate,
m est 2 ou 3,m is 2 or 3,
Ar' est thienyle, benzothiényle, naphtyle, indolyle, N-alcoyl(1- 4C) indolyle, phényle éventuellement mono ou poly substitué par halogène, trifluoromethyle, alcoyle (1 -4C) , alcoyloxy (1-4C), OH ou trifluoromethyle) ,Ar 'is thienyl, benzothienyl, naphthyl, indolyl, N-alkyl (1-4C) indolyl, phenyl optionally mono or poly substituted by halogen, trifluoromethyle, alkyl (1-4C), alkyloxy (1-4C), OH or trifluoromethyl) ,
R est hydrogène ou alcoyle (1-6C),R is hydrogen or alkyl (1-6C),
T est CO ou CONH ou CSNH,T is CO or CONH or CSNH,
Z est soit H, soit M ou OM lorsque T est CO, soit M lorsque T est CONH ou CSNH, M est alcoyle (1-6C), pyridylalcoyle (1 -3C) , naphtylalcoyle (1-3C) éventuellement substitué sur le naphtyle par halogène, trifluoromethyle, alcoyle (1-4C), hydroxy ou alcoyloxy (1-4C), pyridylthioalkyle (1-3C), styryle, phénylalcoyle (1 -3C) éventuellement substitué sur le phényle par un ou plusieurs halogène, trifluoromethyle, alcoyle (1- 4C) , hydroxy oualcoyloxy (1-4C), un groupe aromatique mono, di ou tricyclique éventuellement substitué ou hétéroaromatique mono, di ou tricyclique pouvant porter un ou plusieurs substituants dont un atome de carbone du carbocycle aromatique ou de 1 'hétérocycle aromatique est directement lié au groupe T ou un groupe benzyle éventuellement substitué sur le cycle aromatiques par halogène, trifluoromethyle, alcoyle (-4C) , OH ou alcoyloxy (1-4C),Z is either H, M or OM when T is CO, or M when T is CONH or CSNH, M is alkyl (1-6C), pyridylalkyl (1 -3C), naphthylalkyl (1-3C) optionally substituted on the naphthyl by halogen, trifluoromethyle, alkyl (1-4C), hydroxy or alkyloxy (1-4C), pyridylthioalkyl ( 1-3C), styryl, phenylalkyl (1 -3C) optionally substituted on the phenyl by one or more halogen, trifluoromethyl, alkyl (1-4C), hydroxy oualkyloxy (1-4C), an aromatic group mono, di or tricyclic optionally substituted or heteroaromatic mono, di or tricyclic can carry one or more substituents in which a carbon atom of the aromatic carbocycle or of the aromatic heterocycle is directly linked to the group T or a benzyl group optionally substituted on the aromatic ring by halogen, trifluoromethyl, alkyl (-4C), OH or alkyloxy (1-4C),
Lorsque Z est un aromatique celui-ci peut être par exemple phényle éventuellement substitué, naphtyle éventuellement substitué par [un ou plusieurs halogène, alcoyle (1-4C), phényle, cyano, hydroxyalcoyle (1-4C), hydroxy, oxo, alcoyl (1 -4C) carbonylammo, alcoyloxyd- 4C) carbonyle, thioalcoyle (1-4C)], benzyle éventuellement substitué par un ou plusieurs halogène, trifluoromethyle, alcoyle (1-4C), alcoyloxy (1-4C) ou hydroxy. En particulier lorsque Z est un phényle celui-ci peut être substitué par un ou plusieurs halogène, OH, amino, NHC0NH2, nitro, CONH2, trifluoromethyle, alcoyle (1-10C), alcenyle (2-10C), alcynyle (2-10C), cycloalkyle (3-8C) , bicycloalkyle (4-11C), hydroxyalcoyle (1-5C), alcoyloxy (1-10C), alcoyloxyalcoyle (2-10C), alcoylalcoyloxyalcoyle (3-1 OC), alcoyloxyalcoyloxy (2-1 OC), alcény- loxy (2-10C), alcényloxyalcoyle (2-10C), alcynyloxyalcoyle (3-10C), cycloalcoyloxy (3-8C) , alcoylthio (1-10C), alcoylthioalcoyle (2-10C), acylammo (1-7C), aroylam o, benzylammo, acylammoalcoyle (2-8C, acyloxy (1-6C), alcoyloxycarbonyle (2-5C) cycloalcoyloxycarbonyle (4- 8C) , alcoylammocarbonylammo (2-4C) , dialcoylammocarbonylammo (3- 7C) , (1 -pyrrolidmo) carbonylammo, cycloalcoylammocarbonylammo (4- 8C) , alcoylammocarbonylammoalcoyle (3-9C) , dialcoylammocarbonyla- mmoalcoyle (4-11 C) , (1 -pyrrolidmo) carbonylammoéthyle, (1-pιpérι- dino) carbonylammoéthyle, cycloalcoylammocarbonylammoalcoyle (5- 12C), alcoxycarbonylammoalcoyle (3-12C), cycloalcoyloxycarbonylami- noalcoyle (5-12C), carba oylalcoyle (2-5C) , alcoylammocarbonylal- coyle (3-9C) , dialcoylammocarbonylalcoyle (4-11C), (1-pyrrolι- dme) carbonylméthyle, (1 -pipér dmo) carbonylméthyle, (1-pιpérι- d o) carbonyléthyle, cycloalcoylaminocarbonylalcoyle (2-12C), alcoy- lammocarbonylalcoyloxy (3-1 OC), dialcoylaminocarbonylalcoyloxy (4- 10C), (pιpérιdmyl-1 ) carbonyméthoxy, cycloalcoylam ocarbonylalcoy- loxy (5-11C) .When Z is an aromatic, this may for example be phenyl optionally substituted, naphthyl optionally substituted by [one or more halogen, (1-4C) alkyl, phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, oxo, alkyl ( 1-4C) carbonylammo, alkyloxy-4C) carbonyl, thioalkyl (1-4C)], benzyl optionally substituted by one or more halogen, trifluoromethyl, alkyl (1-4C), alkyloxy (1-4C) or hydroxy. In particular when Z is a phenyl, this can be substituted by one or more halogen, OH, amino, NHCONH 2 , nitro, CONH 2 , trifluoromethyl, alkyl (1-10C), alkenyl (2-10C), alkynyl (2 -10C), cycloalkyl (3-8C), bicycloalkyl (4-11C), hydroxyalkyl (1-5C), alkyloxy (1-10C), alkyloxyalkyl (2-10C), alkylalkyloyloxy (3-1 OC), alkyloxyalkyloyloxy (2 -1 OC), alkenyloxy (2-10C), alkenyloxyalkyl (2-10C), alkynyloxyalkyl (3-10C), cycloalcoyloxy (3-8C), alkylthio (1-10C), alkylthioalkyl (2-10C), acylammo (1-7C), aroylam o, benzylammo, acylammoalkyl (2-8C, acyloxy (1-6C), alkyloxycarbonyl (2-5C) cycloalkyloxycarbonyl (4- 8C), alkylammocarbonylammo (2-4C), dialcoylammocarbonylammo (3-7C) ,, (1 -pyrrolidmo) carbonylammo, cycloalcoylammocarbonylammo (4- 8C), alkylammocarbonylammoalkyl (3-9C), dialcoylammocarbonyla- mmoalkyl (4-11 C), (1 -pyrrolidmo) carbonylammoethyl carbon, ammonium cycloalkyl, coyl (5- 12C), alkoxycarbonylammoalkyl (3-12C), cycloalcoyloxycarbonylaminoalkyl (5-12C), carba oylalkyl (2-5C), alkylammocarbonylal- coyle (3-9C), dialkoylammocarbonylalkyl (4-11C), (1-pyrrolι- dme) carbonylmethyl, (1 -piper dmo) carbonylmethyl, (1-pιpérι- do) carbonylethyl, cycloalcoylaminocarbonylalcoyl (2-12C) alkyl (3-1 OC), dialkoylaminocarbonylalcoyloxy (4-10C), (pιpérιdmyl-1) carbonymethoxy, cycloalcoylam ocarbonylalcoyloxy (5-11C).
Lorsque Z est un hétéroaromatique celui-ci peut être pyridyle, thia- diazolyle, indolyle, mdazolyle, îmidazolyle, benzimidazolyle, benzo- triazolyle, benzofuranyle, benzothiényle, benzothiazolyle, benziso- thiazolyle, quinolyle, îsoqumolyle, benzoxazolyle, benzisoxazolyle, benzodioxmyle, pyridmyle, îsoxazolyle, benzopyranyle , thiazolyle, thienyle, furyle, pyranyle, chroményle, îsobenzofuranyle, pyrrolyle, pyrazolyle, pyrazmyle, pyrimidinyle, pyridazinyle, indolizinyle, phtalazmyle, qu azolinyle, acridmyle, îsothiazolyle, îsochroma- nyle, chromanyle, carbaryle dont une ou plusieurs doubles liaisons peuvent être hydrogénées, ces hétéroaromatiques étant éventuellement substitués par un ou plusieurs alcoyle (1-4C), phényle, cyano, hydroxyalcoyle (1-4C), hydroxy, alcoyl (1 -4C) carbonylam o, alcoyloxyd- 4C)carbonyle ou thioalcoyle (1-4C).When Z is a heteroaromatic it can be pyridyl, thiazidolyl, indolyl, mdazolyl, imidazolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzisothiazolyl, quinolyl, isoquimolyl, benzoxazolyl îsoxazolyl, benzopyranyl, thiazolyl, thienyl, furyl, pyranyl, chromenyl, isobenzofuranyl, pyrrolyl, pyrazolyl, pyrazmyl, pyrimidinyl, pyridazinyl, indolizinyl, phthalazmyl, qu azolinyl, acridmyl, isidiazylyl, isothiazolyl, isothiazolyl may be hydrogenated, these heteroaromatics being optionally substituted by one or more alkyl (1-4C), phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, alkyl (1-4C) carbonylam o, alkylcoxyd- 4C) carbonyl or thioalkyl ( 1-4C).
A titre d'exemple, parmi les dérivés de la classe des amides basiques quaternaires on peut citer ceux de formule générale :By way of example, among the derivatives of the class of quaternary basic amides, mention may be made of those of general formula:
Ar-T-CO-NR-CH2-C(Q) (Ar ' )
Figure imgf000027_0001
Λ
Ar-T-CO-NR-CH 2 -C (Q) (Ar ')
Figure imgf000027_0001
Λ
dans laquelle : Am+ représente un radical : x1in which: Am + represents a radical: x 1
II
X 2-> —N| —© X3X 2 -> —N | - © X 3
pour lequel X1 , X2 , X3 forment ensemble avec l'atome d'azote auquel ils sont liés, un système azabicyclique ou azatricyclique éventuellement substitué par phényle ou benzyle,for which X1, X2, X3 form together with the nitrogen atom to which they are bonded, an azabicyclic or azatricyclic system optionally substituted by phenyl or benzyl,
A- est un anion, Ar est un aromatique ou hétéroaromatique mono, di ou tricyclique pouvant porter un ou plusieurs substituants, dont un atome de carbone du carbocycle ou de l'hétérocycle aromatique est directement lié à T,A- is an anion, Ar is a mono, di or tricyclic aromatic or heteroaromatic which can carry one or more substituents, of which a carbon atom of the carbocycle or of the aromatic heterocycle is directly linked to T,
Ar' est thienyle, benzothiényle, naphtyle, mdolyle ou phényle éven- tuelle ent mono ou poly substitué par halogène, trifluoromethyle, alcoyle (1-4C) ou alcoyloxy (1-3C),Ar 'is thienyl, benzothienyl, naphthyl, mdolyl or phenyl, optionally ent mono or poly substituted by halogen, trifluoromethyl, alkyl (1-4C) or alkyloxy (1-3C),
T est une liaison directe, un groupe hydroxyméthylène , alcoyloxymé- thylène (alcoyle 1 à 4C) ou alkylène (1 à 5 C) ,T is a direct bond, a hydroxymethylene, alkyloxyethylene (1-4C) or alkylene (1-5C) group,
Z est un groupe aromatique ou hétéroaromatique mono, di, ou tricycli- que éventuellement substitué,Z is an optionally substituted mono, di, or tricyclic aromatic or heteroaromatic group,
Q est hydrogène et R est et H, alcoyle (1-4C), ω-alcoyloxy (1 - 4C) alcoyle (2-4C) , ω-alcanoyloxy (2-4C) alcoyle (2-4C) ,Q is hydrogen and R is and H, alkyl (1-4C), ω-alkyloxy (1 - 4C) alkyl (2-4C), ω-alkanoyloxy (2-4C) alkyl (2-4C),
ou bien R et Q forment un groupe 1 , 2-éthylène, 1 , 3-propylène ou 1,4- butylène.or R and Q form a group 1, 2-ethylene, 1, 3-propylene or 1,4-butylene.
Lorsque Ar est un aromatique celui-ci peut être par exemple phényle éventuellement substitué, naphtyle éventuellement substitué par [un ou plusieurs halogène, alcoyle (1-4C), phényle, cyano, hydroxyalcoyle (1-4C), hydroxy, alcoyloxy (1-4C), oxo, alcoyl ( 1 -4C) carbonylammo, alcoyloxy ( 1 -4C) carbonyle, thioalcoyle (1-4C)], mdényle dont une ou plusieurs liaisons peuvent être hydrogénées et éventuellement substitué par [un ou plusieurs halogène, alcoyle (1-4C), phényle, cyano, hydroxyalcoyle (1-4C), hydroxy, alcoyloxy (1-4C), oxo, alcoyl(1- 4C) carbonylammo, alcoyloxy (1 -4C) carbonyle, thioalcoyle (1-4C)]. En particulier lorsque Ar est un phényle celui-ci peut être substitué par un ou plusieurs halogène, 011, amino, NHC0NH2, nitro, C0NH2, trifluoromethyle, alcoyle (1-10C), alcenyle (2-10C), alcynyle (2-10C), cycloalkyle (3-8C), bicycloalkyle (4-11C), hydroxyalcoyle (1-5C), alcoyloxy (1-10C), alcoyloxyalcoyle (2-10C), alcoylalcoyloxyalcoyle (3-1 OC), alcoyloxyalcoyloxy (2-1 OC), alcényloxy (2-1 OC), alcény- loxyalcoyle (2-10C), alcynyloxyalcoyle (3-10C), cycloalcoyloxy (3- 8C) , alcoylthio (1-1 OC) , alcoylthioalcoyle (2-10C), acylammo (1-7C), aroylamino, benzylammo, acylammoalcoyle (2-8C, acyloxy (1-6C), al- coyloxycarbonyle (2-5C) cycloalcoyloxycarbonyle (4-8C) , alcoylam o- carbonylammo (2-4C) , dialcoylammocarbonylammo (3-7C) , (1 -pyrrolidmo) carbonylammo, cycloalcoylammocarbonylam o (4-8C) , alcoylami- nocarbonylaminoalcoyle (3-9C) , dialcoylammocarbonylammoalcoyle (4- 11C), (1 -pyrrolidmo) carbonylammoéthyle, (1-pιpérι- d o) carbonylammoéthyle, cycloalcoylam ocarbonylammoalcoyle (5- 12C), alcoxycarbonylammoalcoyle (3-12C), cycloalcoyloxycarbonylami- noalcoyle (5-12C), carbamoylalcoyle (2-5C) , alcoylammocarbonylal- coyle (3-9C) , dialcoylaminocarbonylalcoyle (4-11C), (1-pyrrolι- dme) carbonylméthyle, (1 -pipéridino) carbonylméthyle, (1-pιpérι- dmo) carbonyléthyle, cycloalcoylaminocarbonylalcoyle (2-12C), alcoy- lammocarbonylalcoyloxy (3-1 OC), dialcoylammocarbonylalcoyloxy (4- 10C) , (pιpérιdmyl-1 ) carbonyméthoxy, cycloalcoylaminocarbonylalcoy- loxy (5-11C) .When Ar is an aromatic, this may for example be phenyl optionally substituted, naphthyl optionally substituted by [one or more halogen, (1-4C) alkyl, phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, alkyloxy (1- 4C), oxo, alkyl (1-4C) carbonylammo, alkyloxy (1-4C) carbonyl, thioalkyl (1-4C)], mdenyl one or more bonds of which can be hydrogenated and optionally substituted by [one or more halogen, alkyl ( 1-4C), phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, alkyloxy (1-4C), oxo, alkyl (1-4C) carbonylammo, alkyloxy (1-4C) carbonyl, thioalkyl (1-4C)] . In particular when Ar is a phenyl, this can be substituted by one or more halogen, 011, amino, NHC0NH 2 , nitro, C0NH 2 , trifluoromethyle, alkyl (1-10C), alkenyl (2-10C), alkynyl (2 -10C), cycloalkyl (3-8C), bicycloalkyl (4-11C), hydroxyalkyl (1-5C), alkyloxy (1-10C), alkyloxyalkyl (2-10C), alkylalkyloyloxy (3-1 OC), alkyloxyalkyloyloxy (2 -1 OC), alkenyloxy (2-1 OC), alkenyloxyalkyl (2-10C), alkynyloxyalkyl (3-10C), cycloalkyloxy (3-8C), alkylthio (1-1 OC), alkylthioalkyl (2-10C) , acylammo (1-7C), aroylamino, benzylammo, acylammoalkyl (2-8C, acyloxy (1-6C), al- coyloxycarbonyle (2-5C) cycloalcoyloxycarbonyle (4-8C), alkyl o-carbonylammo (2-4C), dialcoylammocarbonylammo (3-7C), (1 -pyrrolidmo) carbonylammo, cycloalcoylammocarbonylam o (4-8C), alkylamino- carbonyl -9C), dialkoylammocarbonylammoalkyl (4- 11C), (1 -pyrrolidmo) carbonylammoethyl, (1-pιpérι- do) carbonylammoethyl, cycloalcoylam ocarbonylammoalkyl (5- 12C), alkoxycarbonylammoalkyloycylcoyl (3-12C) alkylcoyl (3-12C) , carbamoylalkoyl (2-5C), alkylammocarbonylalkyl (3-9C), dialkoylaminocarbonylalkyl (4-11C), (1-pyrrolime- carbon) (2-12C), alkylammocarbonylalkoyloxy (3-1 OC), dialkoylammocarbonylalkoyloxy (4- 10C), (pιpérιdmyl-1) carbonymethoxy, cycloalkyllaminocarbonylalkoyloxy (5-11C).
Lorsque Ar est un hétéroaromatique celui-ci peut être pyridyle, thia- diazolyle, indolyle, indazolyle, îmidazolyle, benzimidazolyle, benzo- triazolyle, benzofuranyle, benzothiényle, benzothiazolyle, benziso- th azolyle, quinolyle, îsoqumolyle, benzoxazolyle, benzisoxazolyle, benzodioxinyle, pyrid yle, isoxazolyle, benzopyranyle, thiazolyle, thienyle, furyle, pyranyle, chroményle, isobenzofuranyle, pyrrolyle, pyrazolyle, pyrazmyle, pyrimidmyle, pyridazmyle, mdolizinyle, phtalazmyle, qumazolmyle, acridmyle, îsothiazolyle, îsochroma- nyle, chromanyle, carbaryle dont une ou plusieurs doubles liaisons peuvent être hydrogénées, ces heteroaromatiques étant éventuellement substitués par un ou plusieurs alcoyle (1-4C), phényle, cyano, hydroxyalcoyle (1-4C), hydroxy, alcoyl (1 -4C) carbonylammo, alcoyloxyd- 4C) carbonyle ou thioalcoyle (1-4C).When Ar is a heteroaromatic, it can be pyridyl, thiazidolyl, indolyl, indazolyl, imidazolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzisothiazolol, quinolyl, issoqumolyl, benzidazolyl, benzoxazolyl yl, isoxazolyl, benzopyranyl, thiazolyl, thienyl, furyl, pyranyl, chromenyl, isobenzofuranyl, pyrrolyl, pyrazolyle, pyrazmyle, pyrimidmyle, pyridazmyle, mdolizinyl, phthalazmyl, qumazolmyl, isylamyl, isylazyl, isidiazyl bonds can be hydrogenated, these heteroaromatics being optionally substituted by one or more alkyl (1-4C), phenyl, cyano, hydroxyalkyl (1-4C), hydroxy, alkyl (1-4C) carbonylammo, alkyl-4C-carbonyl or thioalkyl ( 1-4C).
La préparation des produits de formules générales (I) , (II) , (III) , (IV) et (V) peut être effectuée selon les méthodes décrites dans les demandes de brevet EP 429 366, EP 514 273; EP 514 275; EP 528 495; EP 559 538; EP 591 040; EP 635 003; EP 711 280; EP436334; EP693489; WO 90/05729; WO 91/09844; WO 92/12152; WO 92/17449; WO 93/00331; WO 93/01169; WO 93/01170; WO 93/18023; WO 93/21181; WO 94/01402; WO 94/10167; WO 94/19320; WO 95/14017; US 5457107. Parmi les antagonistes de la substance P on peut également citer ceux décrits dans les brevets EP428434, EP429466, EP430771 , EP443132, EP474561 , EP482539, EP499313, EP512902, ΞP517589, EP520555, EP522808, EP532456, EP536817, EP545478, EP566069, EP585913, EP652218, EP655442,The preparation of the products of general formulas (I), (II), (III), (IV) and (V) can be carried out according to the methods described in patent applications EP 429 366, EP 514 273; EP 514,275; EP 528,495; EP 559,538; EP 591,040; EP 635,003; EP 711,280; EP436334; EP693489; WO 90/05729; WO 91/09844; WO 92/12152; WO 92/17449; WO 93/00331; WO 93/01169; WO 93/01170; WO 93/18023; WO 93/21181; WO 94/01402; WO 94/10167; WO 94/19320; WO 95/14017; US 5457107. Among the antagonists of substance P, one can also cite those described in patents EP428434, EP429466, EP430771, EP443132, EP474561, EP482539, EP499313, EP512902, ΞP517589, EP520555, EP522808, EP532456, EP536817, EP54547, EP54547, EP54547 EP655442,
EP707006, EP708101, EP721778, EP723959, WO90/05525, W091/18878, W091/18899, WO92/01688, WO92/06079, W092/12151 , W092/15585,EP707006, EP708101, EP721778, EP723959, WO90 / 05525, W091 / 18878, W091 / 18899, WO92 / 01688, WO92 / 06079, W092 / 12151, W092 / 15585,
WO92/20661 , W092/21677, W092/22569, W092/22596, WO92/23380,WO92 / 20661, W092 / 21677, W092 / 22569, W092 / 22596, WO92 / 23380,
WO92/20676, W092/21677, WO93/00330, WO93/01159, WO93/01165,WO92 / 20676, W092 / 21677, WO93 / 00330, WO93 / 01159, WO93 / 01165,
WO93/03429, WO93/06099, WO93/09116, WO93/10073, WO93/14084, W093/14113, WO93/19064, W093/21181, W093/24465, WO94/00440,WO93 / 03429, WO93 / 06099, WO93 / 09116, WO93 / 10073, WO93 / 14084, W093 / 14113, WO93 / 19064, W093 / 21181, W093 / 24465, WO94 / 00440,
WO94/02461 , WO94/03445, WO94/04487, WO94/04496, WO94/05625,WO94 / 02461, WO94 / 03445, WO94 / 04487, WO94 / 04496, WO94 / 05625,
WO94/07843, WO94/08997, WO94/10165, WO94/10168, WO94/10170,WO94 / 07843, WO94 / 08997, WO94 / 10165, WO94 / 10168, WO94 / 10170,
W094/11368, W094/13639, W094/13663, W094/14767, WO94/15903,W094 / 11368, W094 / 13639, W094 / 13663, W094 / 14767, WO94 / 15903,
WO94/19320, W094/19323, WO94/20500, WO94/26740, WO95/02595, WO95/04042, WO95/06645, WO95/07886, WO95/07908, WO95/08549,WO94 / 19320, W094 / 19323, WO94 / 20500, WO94 / 26740, WO95 / 02595, WO95 / 04042, WO95 / 06645, WO95 / 07886, WO95 / 07908, WO95 / 08549,
W095/16679, W095/17382, W095/18124, W095/18129, W095/19344,W095 / 16679, W095 / 17382, W095 / 18124, W095 / 18129, W095 / 19344,
WO95/20575, W095/21819, W095/22525, W095/26335, W095/26338,WO95 / 20575, W095 / 21819, W095 / 22525, W095 / 26335, W095 / 26338,
W095/26339, W095/33744, WO96/07649, W096/18643, W096/2'661 ,W095 / 26339, W095 / 33744, WO96 / 07649, W096 / 18643, W096 / 2'661,
W095/11895, WO96/10562, US5162339, US5232929, US5496833, FR2696178, FR2717802, FR2717804, FR2729952, FR2729953, FR2729954.W095 / 11895, WO96 / 10562, US5162339, US5232929, US5496833, FR2696178, FR2717802, FR2717804, FR2729952, FR2729953, FR2729954.
Parmi les antagonistes de la substance P on peut notamment citer les produits suivants : LY303870, CP122721, CP96345, CP122999, CP99994, FK888, GR205171, GR203040, L709210, L733060, L736281 , L732138, L737488, L740141, L741671, L747264, CGP47899, CGP49823, CGP49823, SR140333.Among the antagonists of substance P, the following products may in particular be mentioned: LY303870, CP122721, CP96345, CP122999, CP99994, FK888, GR205171, GR203040, L709210, L733060, L736281, L732138, L737488, L740141, L740141, L740147 , CGP49823, SR140333.
L'activité des antagonistes de la substance P, qui traversent la barrière hématoencéphalique, dans le traitement des dyskinésies a été mise en évidence dans le modèle des dyskinésies induites par l'halopéridol chez le rat:The activity of substance P antagonists, which cross the blood-brain barrier, in the treatment of dyskinesias has been demonstrated in the model of dyskinesias induced by haloperidol in rats:
PRINCIPE :PRINCIPLE:
Le modèle des dyskinésies induites par l'halopéridol (un neuroleptique classique) est caractérisé par des mouvements involontaires de la bouche, du visage, de la langue connus sous le nom de syndrome de « Vacuous Chew g Movement » (VCM) [J0ergensen et coll. Psychopharma- cology, 116:89-92 (1994); Waddmgton Psychopharmacology, 101 : 431- 447 (1990)].The model of dyskinesias induced by haloperidol (a classic neuroleptic) is characterized by involuntary movements of the mouth, face, tongue known as "Vacuous Chew g Movement" (VCM) [J0ergensen et al. Psychopharma- cology, 116: 89-92 (1994); Waddmgton Psychopharmacology, 101: 431-447 (1990)].
La forme décanoate d'halopéridol est capable d'induire chez le rat dès la 4ème semaine après l'infection, un nombre important de mouvements buccolinguaux (très similaires aux mouvements dyskinetiques survenant chez l'homme suite à une administration chronique de neuroleptiques) .The decanoate form of haloperidol is capable of inducing in rats from the 4th week after infection, a large number of buccolinguinal movements (very similar to dyskinetic movements occurring in humans following chronic administration of neuroleptics).
TECHNIQUE :TECHNICAL:
Des rats maies Sprague-Dawley pesant 200-220 g sont gardés pendant au moins 5 jours avant leur utilisation. Les rats sont groupés par 3, avec accès libre à la nourriture et à l'eau. Le matin de l'expérience la nourriture et l'eau sont supprimées pour la durée de l'expérience.Maize Sprague-Dawley rats weighing 200-220 g are kept for at least 5 days before use. The rats are grouped in groups of 3, with free access to food and water. In the morning of the experience, food and water are removed for the duration of the experience.
40 mg/kg de décanoate d'halopéridol (0,8 ml/kg) sont injectés aux animaux par voie intra-musculaire pour induire des dyskinésies orofa- ciales. (Jorgensen et al., Psychopharmacol . , 116, 89 (1994). Les animaux contrôles reçoivent un volume équivalent de véhicule utilisé pour l'halopéridol.40 mg / kg of haloperidol decanoate (0.8 ml / kg) are injected into the animals by intramuscular route to induce orofacial dyskinesia. (Jorgensen et al., Psychopharmacol., 116, 89 (1994). The control animals receive an equivalent volume of vehicle used for haloperidol.
6 semaines après 1 'injection de décanoate d'halopéridol les animaux reçoivent l'antagoniste de la substance P, par voie mtra-périto- néale, ou son excipient. Le comportement dyskinétique caractérisé par des mouvements involontaires anormaux bucco-linguaux est mesuré en comptant le nombre de mâchonements pendant 2 périodes de 30 minutes d'observation chacunes : l'une précédant l'administration de la molé- cule à tester et l'autre 30 minutes après l'administration de cette molécule. Les mesures sont comparées. Un produit active est un produit qui réduit significativement le nombre de mouvements involontaires évalués après son administration par rapport au nombre de mouvements involontaires évalués avant son administration.6 weeks after the injection of haloperidol decanoate, the animals receive the substance P antagonist, mtra-peritoneally, or its excipient. Dyskinetic behavior characterized by abnormal involuntary buccolingual movements is measured by counting the number of chews during 2 periods of 30 minutes of observation each: one preceding the administration of the molecule to be tested and the other 30 minutes after the administration of this molecule. The measurements are compared. An active product is a product which significantly reduces the number of involuntary movements evaluated after its administration compared to the number of involuntary movements evaluated before its administration.
RÉSULTATS :RESULTS:
Les produits suivants ont été étudiés : Produit 1 : [imino-1 (méthoxy-2 phényl) -2 éthyl]-2 diphényl-7,7 perhydroisoindolone-4- (3aR,7aR) :The following products have been studied: Product 1: [imino-1 (2-methoxyphenyl) -2 ethyl] -2 diphenyl-7,7 perhydroisoindolone-4- (3aR, 7aR):
Figure imgf000032_0001
Figure imgf000032_0001
Produit 2 : { (R) -1 - [N- (2-méthoxybenzyl) acetylamino] -3- (1H-indol-3- yl) -2- [N- (2- (4- (pipéridin-1 -yl) piperidin-1 -yl) acetylamino] -propane}Product 2: {(R) -1 - [N- (2-methoxybenzyl) acetylamino] -3- (1H-indol-3- yl) -2- [N- (2- (4- (piperidin-1 -yl ) piperidin-1 -yl) acetylamino] -propane}
Figure imgf000032_0002
Figure imgf000032_0002
Produit 3 : Dichlorhydrate de (2S, 3S) -3- (2-méthoxy-5-trifluoromé- thoxybenzyl) -amino-2-phényl-pipéridine :Product 3: (2S, 3S) -3- (2-methoxy-5-trifluoromethoxybenzyl) -amino-2-phenyl-piperidine dihydrochloride:
Figure imgf000032_0003
Figure imgf000032_0003
N H ,2HC1N H, 2HC1
V Tableau IV Table I
Figure imgf000033_0001
Figure imgf000033_0001
A des doses de 10 à 30 mg/kg i.p. les produits étudiés inhibent de 47 à 69 % des mouvements oraux anormaux de mâchonnement.At doses of 10 to 30 mg / kg i.p. the products studied inhibit from 47 to 69% of abnormal oral chewing movements.
La présente invention concerne également la préparation de compositions pharmaceutiques comprenant un antagoniste de la substance P capable de passer la barrière hématoencéphalique, à l'état pur ou sous forme d'une association avec un ou plusieurs diluants et/ou adjuvants compatibles et pharmaceutiquement acceptables et/ou éventuellement en association avec tout autre produit pharmaceutiquement compatible physiologiquement actif, destinées au traitement des dyskinésies liées aux maladies du système nerveux central.The present invention also relates to the preparation of pharmaceutical compositions comprising a substance P antagonist capable of crossing the blood-brain barrier, in the pure state or in the form of a combination with one or more compatible and pharmaceutically acceptable diluents and / or adjuvants and / or optionally in combination with any other physiologically active pharmaceutically compatible product, intended for the treatment of dyskinesias linked to diseases of the central nervous system.
Les compositions préparées selon l'invention peuvent être utilisées par voie parentérale, orale, rectale, transdermique et aérosols.The compositions prepared according to the invention can be used parenterally, orally, rectally, transdermally and aerosols.
Les compositions stériles pour administration parentérale qui peuvent être notamment utilisées sous forme de perfusions sont de préférence des solutions aqueuses ou non aqueuses, des suspensions ou des émul- sions. Comme solvant ou véhicule, on peut employer l'eau, le propylè- neglycol, un polyéthylèneglycol, des huiles végétales, en particulier l'huile d'olive, des esters organiques injectables, par exemple l'oléate d'éthyle ou d'autres solvants organiques convenables. Ces compositions peuvent également contenir des adjuvants, en particulier des agents mouillants, isotonisants, émulsifîants , dispersants et stabilisants. La stérilisation peut se faire de plusieurs façons, par exemple par filtration aseptisante, en incorporant à la composition des agents stérilisants, par irradiation ou par chauffage. Elles peuvent également être préparées sous forme de compositions solides stériles qui peuvent être dissoutes au moment de 1 ' emploi dans un milieu stérile injectable.The sterile compositions for parenteral administration which can in particular be used in the form of infusions are preferably aqueous or non-aqueous solutions, suspensions or emulsions. As solvent or vehicle, it is possible to use water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or the like. suitable organic solvents. These compositions can also contain adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. Sterilization can be done in several ways, by for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in a sterile injectable medium.
Les compositions pour administration rectale sont des suppositoires ou des capsules rectales, qui contiennent outre le produit actif des excipients tels que le beurre de cacao, des glycérides semi-synthéti- ques ou des polyéthylèneglycols .The compositions for rectal administration are suppositories or rectal capsules, which contain, in addition to the active product, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
Les compositions solides pour administration orale peuvent être des gélules , des comprimés , des pilules , des poudres ou des granulés . Dans ces compositions, le principe actif (éventuellement associé à un autre produit pharmaceutiquement compatible) est mélangé à un ou plusieurs diluants ou adjuvants inertes, tels que saccharose, lactose ou amidon. Ces compositions peuvent également comprendre des substances autres que les diluants, par exemple un lubrifiant tel que le stéarate de magnésium.The solid compositions for oral administration can be capsules, tablets, pills, powders or granules. In these compositions, the active principle (optionally associated with another pharmaceutically compatible product) is mixed with one or more inert diluents or adjuvants, such as sucrose, lactose or starch. These compositions can also include substances other than diluents, for example a lubricant such as magnesium stearate.
Les compositions liquides pour administration orale, peuvent être des émulsions pharmaceutiquement acceptables, des solutions, des suspen- sions, des sirops et des élixirs contenant des diluants inertes tels que l'eau ou l'huile de paraffine. Ces compositions peuvent également comprendre des substances autres que les diluants, par exemple des produits mouillants, édulcorants ou aromatisants.The liquid compositions for oral administration can be pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents such as water or paraffin oil. These compositions can also include substances other than diluents, for example wetting, sweetening or flavoring products.
Les compositions pour administration topique peuvent être par exemple des crèmes, des pommades, ou des lotions.The compositions for topical administration can be, for example, creams, ointments, or lotions.
Les compositions peuvent également être des aérosols. Pour l'usage sous forme d'aérosols liquides, les compositions peuvent être des solutions stériles stables ou des compositions solides dissoutes au moment de l'emploi dans de l'eau stérile apyrogène, du sérum ou tout autre véhicule pharmaceutiquement acceptable. Pour l'usage sous forme d'aérosols secs destinés à être directement inhalés, le principe actif est est finement divisé et associé à un diluant ou véhicule so- lide hydrosoluble d'une granulometrie de 30 à 80 um, par exemple le dextrane, le mannitol ou le lactose.The compositions can also be aerosols. For use in the form of liquid aerosols, the compositions can be stable sterile solutions or solid compositions dissolved at the time of use in sterile pyrogen-free water, serum or any other pharmaceutically acceptable vehicle. For the use in the form of dry aerosols intended to be directly inhaled, the active principle is is finely divided and associated with a diluent or vehicle water-soluble liquid with a particle size of 30 to 80 μm, for example dextran, mannitol or lactose.
D'une façon générale, le médecin déterminera la posologie qu'il estime la plus appropriée en fonction de l'âge, du poids et de tous les autres facteurs propres au sujet à traiter. Les doses dépendent de l'effet recherché et de la durée du traitement. Pour un adulte, elles sont généralement comprises entre 0,25 et 2500 mg par jour en prises échelonnées .In general, the doctor will determine the dosage he considers most appropriate based on age, weight and all other factors specific to the subject to be treated. The doses depend on the desired effect and on the duration of the treatment. For an adult, they are generally between 0.25 and 2500 mg per day in staggered doses.
L'exemple suivant, donné à titre non limitatif, illustre une corαposi- tion préparée selon l'invention et destinée au traitement des dyskinésies.The following example, given without limitation, illustrates a composition prepared according to the invention and intended for the treatment of dyskinesias.
ExempleExample
On prépare, selon la technique habituelle, des comprimés de produit actif ayant la composition suivante :Active product tablets having the following composition are prepared according to the usual technique:
- [imino-1 (méthoxy-2 phényl) -2 éthyl] -.. diphényl-7,7 perhydroisoindolone-4- (3aR, 7aR) 25 mg- [imino-1 (2-methoxyphenyl) -2 ethyl] - .. diphenyl-7,7 perhydroisoindolone-4- (3aR, 7aR) 25 mg
- amidon 83 mg- starch 83 mg
- silice 30 mg- silica 30 mg
- stéarate de magnésium 3 mg - magnesium stearate 3 mg

Claims

REVENDICATIONS
1 - Application de principes actifs doués d'une activité antagoniste de la substance P et capables de passer la barrière hématoencéphalique, pour la préparation d'un médicament destiné au traitement des dyskinésies liées aux maladies du système nerveux central.1 - Application of active principles endowed with an antagonistic activity of substance P and capable of crossing the blood-brain barrier, for the preparation of a medicament intended for the treatment of dyskinesias linked to diseases of the central nervous system.
2 - Application selon la revendication 1 , pour la préparation d'un médicament destiné au traitement des dyskinésies tardives.2 - Application according to claim 1, for the preparation of a medicament for the treatment of tardive dyskinesias.
3 - Application selon la revendication 1 ou 2 , caractérisée en ce que les principes actifs doués d'une activité antagoniste de la substance P, capables de passer la barrière hématoencéphalique sont choisis parmi la classe des dérivés du dιamιno-1,2 éthane ou de l'acylammo- 1 ammo-2 éthane antagonistes des récepteurs à tachykinines non pep- tidiques, la classe des perhydroisoindoles , la classe des 3-amιno- quιnuclιdmes-2-substιtuées, la classe des pipéridines 2, 3-dιsubstι- tuées, la classe des 3-amιno-pιpérιdmes-2-substιtuées, la classe des dérivés trisubstitués de la morpholine, la classe des dérivés aromatiques substitués, la classe des sels quaternaires de pipéridines substituées, ou des amides basiques quaternaires.3 - Application according to claim 1 or 2, characterized in that the active principles endowed with an antagonistic activity of substance P, capable of passing the blood-brain barrier are chosen from the class of derivatives of 1,2-dιamιno ethane or acylammo- 1 ammo-2 ethane antagonists of non-pep- tidic tachykinin receptors, the class of perhydroisoindoles, the class of 3-amιno- quιnuclιdmes-2-substituted, the class of piperidines 2, 3-disubstituted, the class of 3-amιno-pιpérιdmes-2-substituted, class of trisubstituted morpholine derivatives, class of substituted aromatic derivatives, class of quaternary salts of substituted piperidines, or basic quaternary amides.
4 - Application selon l'une des revendications 1 à 3 caractérisée en ce que les principes actifs doués d'une activité antagoniste de la substance P, capables de passer la barrière hématoencéphalique sont choisis parmi l'[ιmιno-1 (méthoxy-2 phényl)-2 éthyl]-2 dιphényl-7,7 perhydroιsoιndolone-4- (3aR, 7aR) , le { (R) -1 - [N- (2-méthoxyben- zyl) acetylamino] -3- (1H-mdol-3-yl) -2- [N- (2- (4- (pιpérιdm-1- yl) pιperιdm-1 -yl) acetylamino] -propane} , le dichlorhydrate de (2S,3S) -3- (2-méthoxy-5-tπfluorométhoxybenzyl) -ammo-2-phényl-pιpé- ridme.4 - Application according to one of claims 1 to 3 characterized in that the active principles endowed with an antagonistic activity of substance P, capable of passing the blood-brain barrier are chosen from [ιmιno-1 (2-methoxy-phenyl ) -2 ethyl] -2 dιphenyl-7,7 perhydroιsoιndolone-4- (3aR, 7aR), {(R) -1 - [N- (2-methoxybenzyl) acetylamino] -3- (1H-mdol- 3-yl) -2- [N- (2- (4- (pιpérιdm-1- yl) pιperιdm-1 -yl) acetylamino] -propane}, (2S, 3S) -3- (2-methoxy) hydrochloride -5-tπfluorométhoxybenzyl) -ammo-2-phenyl-pιpé-ridme.
5 - Composition pharmaceutique destinée à l'application selon l'une des revendications 1 à 4.5 - Pharmaceutical composition intended for the application according to one of claims 1 to 4.
6 Préparation d'une composition pharmaceutique destinée à l'application selon l'une des revendications 1 à 4. 6 Preparation of a pharmaceutical composition intended for the application according to one of claims 1 to 4.
PCT/FR1997/001914 1996-10-29 1997-10-24 Use of antagonists of substance p for treating tardive diskinesia WO1998018465A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49514/97A AU4951497A (en) 1996-10-29 1997-10-24 Use of antagonists of substance p for treating tardive diskinesia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613175A FR2755013B1 (en) 1996-10-29 1996-10-29 NEW THERAPEUTIC APPLICATION OF P SUBSTANCE ANTAGONISTS
FR96/13175 1996-10-29

Publications (1)

Publication Number Publication Date
WO1998018465A1 true WO1998018465A1 (en) 1998-05-07

Family

ID=9497133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/001914 WO1998018465A1 (en) 1996-10-29 1997-10-24 Use of antagonists of substance p for treating tardive diskinesia

Country Status (3)

Country Link
AU (1) AU4951497A (en)
FR (1) FR2755013B1 (en)
WO (1) WO1998018465A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925627A (en) * 1996-12-02 1999-07-20 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating movement disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US8685714B2 (en) 2000-07-14 2014-04-01 Universal Biosensors Pty Ltd Immunosensor
US9863942B2 (en) 2002-03-21 2018-01-09 Universal Biosensors Pty Ltd Biosensor apparatus and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430771A1 (en) * 1989-11-23 1991-06-05 Rhone-Poulenc Sante Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists
US5216018A (en) * 1992-02-14 1993-06-01 Du Pont Merck Pharmaceutical Company Hydroisoindolines and hydroisoquinolines as psychotropic
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US5541217A (en) * 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430771A1 (en) * 1989-11-23 1991-06-05 Rhone-Poulenc Sante Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists
US5216018A (en) * 1992-02-14 1993-06-01 Du Pont Merck Pharmaceutical Company Hydroisoindolines and hydroisoquinolines as psychotropic
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US5541217A (en) * 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.G. NUTT ET AL.: "Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.", NEUROLOGY, vol. 30, no. 12, 1980, pages 1280 - 1285, XP002034879 *
L.M. GUNNE ET AL.: "Neurobiochemical changes in tardive diskinesia.", ENCEPHALE, vol. 14, 1988, pages 167 - 173, XP002034878 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925627A (en) * 1996-12-02 1999-07-20 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating movement disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US8685714B2 (en) 2000-07-14 2014-04-01 Universal Biosensors Pty Ltd Immunosensor
US9863942B2 (en) 2002-03-21 2018-01-09 Universal Biosensors Pty Ltd Biosensor apparatus and methods of use

Also Published As

Publication number Publication date
FR2755013A1 (en) 1998-04-30
AU4951497A (en) 1998-05-22
FR2755013B1 (en) 1998-11-27

Similar Documents

Publication Publication Date Title
EP1328269B2 (en) Association of a cb1 receptor antagonist and sibutramin for treating obesity
TWI363625B (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
RU2157205C2 (en) Application of riluzole for treatment of neurological aids and a method for preparation of drug
CZ284363B6 (en) The application of anticonvulsive agent being selected from a group containing carbamazepine and oxcarbazepine
RU2008142957A (en) METHODS FOR PRODUCING A FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENS MUTATION AND TREATING DISORDERS ASSOCIATED WITH IT
JP2008536853A (en) Combinations, methods and compositions for the treatment of cancer
US20100099714A1 (en) AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
TW200808743A (en) Compositions and methods of treating CNS disorders
CA2152401C (en) Synergising association having an antagonist effect on nk1 and nk2 receptors
WO1999058117A1 (en) Use of compounds for reducing apoptosis
CA2103516A1 (en) Therapeutical application of fluoroquinolone derivatives
EP0437128B1 (en) Use of derivatives of fluoroquinolone in the treatment of pneumocystis carinii pneumonia
WO1998018465A1 (en) Use of antagonists of substance p for treating tardive diskinesia
CA2129962A1 (en) Therapeutic use of phenothiazine derivatives
WO2001024791A1 (en) Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders
CZ285633B6 (en) Use of indole derivatives for preparing medicaments
JP2000501118A (en) Synergistic immunosuppressant composition containing 2,2&#39;-bi-1H-pyrrole compound
JPH02502545A (en) Dextromethorphan synergistic agent for anti-convulsant compositions and methods
FR2684552A1 (en) USE OF D-FENFLURAMINE AND FENFLURAMINE DERIVATIVES IN THE TREATMENT OF HYPERTENSION IN INSULIN-RESISTANT SUBJECTS.
FR2734724A1 (en) APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF ALCOHOLISM
FR2544614A1 (en) NEW DRUG ASSOCIATION FOR THE TREATMENT OF HYPERTENSION
TWI325317B (en) Appetite-stimulating agents and remedies for anorexia
FR2774596A1 (en) USE OF SELENATED COMPOUNDS IN THE PREVENTION AND TREATMENT OF ALZHEIMER&#39;S DISEASE
CA2164286C (en) Indole derivatives in the treatment of emesis
ES2322538T3 (en) INHIBITORS AGAINST THE INCREASE OF EYE TENSION CAUSED BY IRRADIATION WITH LASERES, WHICH CONTAIN DERIVATIVES OF 1,4-DIHYDROPIRIDINE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GH HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase